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Abstract
Despite mounting concern over the increased risk of cardiovascular disease in breast
cancer patients, studies evaluating the common genetic/molecular link between these
diseases are limited. Mutations in the breast cancer susceptibility genes (BRCA1&2)
predispose carriers to breast and ovarian cancers due to compromised DNA damage
repair capacity leading to DNA damage accumulation; in cancer cells, and in other celltypes including endothelial cells, causing atherosclerotic hallmarks of endothelial
dysfunction/apoptosis. We present a new understanding of BRCA2’s protective
functionality in the setting of atherosclerosis. Studies have thus far demonstrated that
while loss of endothelial BRCA2 in mice does not affect a molecular or functional baseline
phenotype, endothelial cell-specific loss of BRCA2 exacerbates high-fat diet-induced
atherosclerosis in ApoE-/- mice. This study illuminates BRCA2 as a potential therapeutic
target in cardiovascular disease and suggests a requirement for studies evaluating the
genetic predisposition of BRCA2-mutation carriers for increased risk of atherosclerosis
and other cardiovascular diseases.
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Summary for Lay Audience
In Canada, as in most developed countries, the cardiovascular disease atherosclerosis
which is the buildup of vessel-occluding plaque, is a leading cause of illness and death.
According to the most recent data, one in five deaths in Canada is due to atherosclerosisassociated cardiovascular dysfunction. Despite great medical advances, therapies are
urgently needed to improve cardiovascular function in atherosclerosis. Endothelial cells,
which line the innermost layer of blood vessels, play important roles in maintaining blood
vessel function. Understanding the mechanisms underlying abnormal endothelial
function may serve to uncover novel therapeutic approaches to treat atherosclerosis and
associated cardiovascular dysfunctions. DNA is the genetic material present in every cell
type, and it is prone to damage by various stressors. BRCA2 is a protein molecule, which
maintains DNA integrity by repairing the damaged DNA. Loss of BRCA2 function causes
breast and ovarian cancer. DNA damage not only causes cancer but also plays important
role in the development of cardiovascular diseases. Our aim is to understand if the loss of
endothelial BRCA2 results in increased endothelial cell death, endothelial dysfunction,
and if it also promotes atherosclerosis-associated cardiovascular diseases. In this thesis,
we will use an animal model of atherosclerosis which lacks BRCA2, only in their
endothelial cells. We aim to investigate if there will be increased atherosclerosisassociated endothelial dysfunction and endothelial cell death after feeding these animals
a high fat diet. Our study will delineate a new role of BRCA2 in atherosclerosis, which may
help identify BRCA2 as a new therapeutic target to treat cardiovascular diseases. Our
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study may also indicate a cancer-independent increased susceptibility of cardiovascular
disease development in carriers of a BRCA2 mutation.
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Chapter 1. Introduction
1.1 Overview: Cardiovascular disease (CVD) is a leading cause of death and morbidity in
developed nations, and there are many overlapping characteristics between cancer and
CVD. Atherosclerosis is an inflammatory cardiovascular disease of the cells lining the
vasculature (endothelial cells), wherein DNA damage and apoptosis occur as disease
hallmarks and are overlapping factors with cancer. The breast cancer susceptibility gene
2 (BRCA2) repairs DNA damage and protects against apoptosis; this mechanism may play
a role in mitigating atherosclerosis – warranting the study of BRCA2 in CVD progression.
This research was performed to determine if BRCA2 has anti-atherosclerotic properties
and contextualize BRCA2 within the landscape of cardio-oncology. We aim to cultivate
progress and a better understanding of the molecular roles and clinical implications of
disrupted BRCA2 function. By doing so, we may provide an impetus for expanded BRCA2
screening and the development of novel therapeutics to advance patient care for those
carrying a BRCA2 mutation.
1.2 Thesis Outline: The work herein seeks to address two main points. 1) We address if
mice with endothelial cell-specific Cre-mediated deletion of BRCA2 have a baseline
phenotype. Assessing the effect of EC-specific loss of BRCA2 without stress will provide a
foundational understanding of this model and will further help delineate the effect of
disease-related stress in the same mouse model. 2) We determine if BRCA2endo mice on
an ApoE-/- background, fed a high-fat diet, demonstrate a genotype-dependent
exacerbation of atherosclerosis compared to the ApoE-/- mice.
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Chapter 2. Literature Review and Background
2.1 Tumor Suppressor Genes: Tumor suppressor genes are genes wherein loss of function
may promote cancer through unmitigated growth and proliferation. They are subdivided
into caretakers, which maintain genomic integrity, and gatekeepers, such as tumor
protein 53 (TP53/p53), which control proliferation, differentiation, and apoptosis;
thereby regulating tumorigenesis.(Heemst et al., 2007)(Kinzler & Vogelstein, 1997)
Inactivation of both types of tumor-suppressor genes synergistically enhances
tumorigenic potential. BReast CAncer Susceptibility genes 1 and 2 (BRCA1&2) are prime
examples of caretakers; importantly though, they also provide gatekeeper functionality
by virtue of their participation in cell cycle regulation and DNA stabilization, which
regulates cellular homeostasis. Thus, BRCA1&2 are key genes of interest in cancer, as well
as diseases of disrupted cellular homeostasis.
2.2 BRCA1&2: The BRCA1&2 share the tumor suppressor classification primarily as
caretakers on the basis of their determined role in a common pathway of homologous
recombination repair (HRR).(Roy et al., 2012) The BRCA1 gene-product is 1863 amino
acids in length; its gene is located on the long arm of chromosome 17 at the position 21.31,
encompassing 22 exons coding for a 220kDa protein (Figure 2-1). BRCA2 is comprised of
3418 amino acids; its gene is found on the long arm of chromosome 13 at position 13.1
and contains 26 coding exons that produce a 384kDa protein (Figure 2-1). Both BRCA1
and 2 proteins are produced in the cytosol and contain nuclear localization signals for
nuclear trans-localization – enabling their function as DNA damage repair proteins.
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2.3 DNA Damage and Repair: DNA damage represents a constant threat to cellular
equilibrium. It arises from a multitude of sources, and, depending on the source and cell
type, the number of events range from between less than 1 to over 100,000 times per cell
per day.(Ciccia & Elledge, 2010) This ultimately results in an estimated intergenerational
mutation rate of 1.1 x 10-8 per site.(Roach et al., 2010)
Exogenous DNA damage results from exposures to externally derived environmental
factors such as chemicals or ultraviolet (UV) and ionizing radiation, causing modifications
to the structure of nucleic acids.(Hakem, 2008) Endogenous DNA damage typically occurs
as DNA undergoes hydrolysis or engages in chemical reactions with electrophiles or
reactive species.(Marnett & Plastaras, 2001) Even the tightly regulated process of DNA
replication and repair may generate enzymatically driven polymerization errors.(Sharma
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& Chowdhury, 2012) Therefore, cells require different strategies and machinery in the
form of the DNA damage response (DDR) pathway to recognize and repair the various
types of genomic damage and alterations. While there is some redundancy, loss of
function of primary repair or sensing protein mechanisms in the DDR pathway results in
unchecked damage, mutations, and cellular dysregulation; these events enable the
accumulation of DNA damage, which progressively overwhelms cellular repair capacity
and results in genomic instability.(Negrini et al., 2010) Repair strategies vary depending
on different factors including the type of DNA damage and during which phase of the cell
cycle the damage occurs. While some lesions in the DNA may be directly fixed by chemical
reaction through a repair strategy known as direct reversal,(Ca et al., 2020)(Ragg et al.,
2000) extensive genomic insult requires more elaborate repair networks.
Single-stranded break (SSB) damage is a discontinuation of one strand of the double helix
and commonly results from oxidative stress,(Caldecott, 2008) ionizing radiation, or occurs
during the repair of UV radiation-induced damage.(Myllyperkiö et al., 1999)
Consequences of SSBs include replication fork collapse and transcriptional
blocking.(Caldecott, 2008) SSBs are repaired by excision; specifically, base excision repair
(BER) or nucleotide excision repair (NER) mechanisms, which recognize and remove one
to multiple damaged bases, respectively,(Hakem, 2008) before DNA polymerase utilizes
the opposite strand as a repair template.
Double-stranded breaks (DSBs) are a full cleavage of the double helix structure of DNA.
They occur via oxidative stress or the introduction of genotoxic agents such as ionizing
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radiation and chemotherapeutics. These breaks have the potential to be the most
deleterious for genomic integrity, and the outcome of their repair is mechanism and cell
cycle dependent.
Non-Homologous End Joining (NHEJ) of DSBs takes place without a template, and
consequently, the re-attachment of broken DNA occurs through end trimming and
resection.(Hakem, 2008) Subsets of this are alternative non-homologous end joining (ANHEJ) and microhomology-mediated end joining (MMEJ). In the G1 phase, the absence
of a sister chromatid requires that repair of DSBs occurs through NHEJ(Mathiasen & Lisby,
2014)(Zhao et al., 2017) or MMEJ,(Yun & Hiom, 2009) however, DSB repair in the absence
of homology is prone to errors and deletions and thus, this method will inevitably result
in mutation at the site of repair.(Chang et al., 2017)
Homology directed repair, or homologous recombination repair (HRR), of DSBs occurs
when there is a homologous chromosome or sister chromatid available to be used as the
template. HRR is the error-free preferred method during the S and G2 phases of the cell
cycle.(Zhao et al., 2017)(Mathiasen & Lisby, 2014) Homology directed repair pathway is
quintessential for genomic maintenance and is the pathway along which BRCA1&2
operate.
2.4 Homology Directed Repair Pathway: Homologous Recombination Repair (Figure 2-2)
involves a complex network of proteins that sense DNA damage and initiate a signalling
cascade that effects the virtually error-free DSB repair mechanism using complementary
DNA or a sister chromatid.
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Figure 2-2. Overview of the Homologous Recombination Repair Pathway. Upon sensing
a double stranded break in the DNA, if a homologous duplex is available as a template,
HRR is initiated. 5’-3’ end resection creates overhanging ssDNA which invades the
template via Holiday junctions. The invading strand pairs with homologous sequences in
the template DNA; an action facilitated by Rad51. DNA synthesis is followed by second
end recapture to anneal the newly synthesized DNA to the original strand resulting in
linear DNA (Created with BioRender).
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2.4.1 Pathway Activation (Figure 2-3): DSBs signal ataxia telangiectasia mutated (ATM)
dimers to undergo autophosphorylation and disassociation, activating the monomeric
ATM kinase.(Kastan & Bakkenist, 2003)(Harper & Elledge, 2007)(Merechal, A., Zou, 2013)
ATM activation is further mediated by its interaction with a FXF/Y motif located at the Cterminus of Nijmegen breakages syndrome 1 (NSB1) of the MRE11-RAD50-NSB1 (MRN)
complex, and upon its recruitment to damaged DNA.(You et al., 2005) Ataxia
telangiectasia (ATR), another prominent DDR kinase is activated in response to both SSBs
and DSBs.(Merechal, A., Zou, 2013)
The MRN complex tethers the damaged DNA, thereby concentrating it, and the ATM
kinase phosphorylates a vast number of proteins, including BRCA1, mediator of DNA
damage checkpoint 1 (MDC1), p53, checkpoint kinase 1 (Chk1), checkpoint kinase 2
(Chk2), and histone H2AX – a set of reactions that influences repair factors to form at the
site of DNA damage and triggers HRR and cell cycle arrest pathways.(Dupré et al.,
2006)(Matsuoka et al., 2007)(Podhorecka et al., 2010)(Bonner et al., 2008)(Merechal, A.,
Zou, 2013)(Harper & Elledge, 2007) MDC1 bridges DNA damage repair and cell cycle
checkpoint activation through distinct phospho-dependent interactions; the carboxylterminal (C-terminal) of BRCA1 C terminus (BRCT) region MDC1 associates with yH2AX to
aide in DSB repair while MDC1-MRN complex interaction facilitates intra-S-phase
checkpoint activation.(Stucki et al., 2005)(Goldberg et al., 2003) The ring finger ubiquitin
ligase, ring finger protein 8 (RNF8), accumulates alongside NSB1, whereafter they bind to
phosphorylated MDC1(Chapman & Jackson, 2008) – RNF8 to its FHA domain – and
assemble at the site of DSB DNA damage(Mailand et al., 2007) where, through association
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with chromodomain helicase DNA binding protein 4 (CHD4), RNF8 mediates chromatin
decondesation, providing damage site accessibility by repair factors (Luijsterburg et al.,
2012) including BRCA1&2-associated complexes.
2.4.2 BRCA1-associated Interactions (Figure 2-3): The RING domain of BRCA1
ubiquitinates the endonuclease CtBP-interacting protein (CtIP) where, under DNA
damage conditions, ubiquitinated CtIP is targeted to the chromatin where it aides in end
resection and cell cycle checkpoint control of the G2/M phase.(X. Yu et al., 2006) BRCA1CtIP interaction determines the choice between error-prone MMEJ and the relatively
error-free HRR in a cell-cycle phase-dependent manner; CtIP activates MMEJ in the G1
phase while phosphorylation of its serine residue 327 as cells enter S phase allows a
switch to HR during S/G2 phase with BRCA1 recruitment.(Yun & Hiom, 2009) The MRNCtIP-BRCA1 pathway readies DNA for HR-related end resection in S-phase via
Topoisomerase-II DNA adduct removal.(Yun & Hiom, 2009)
BRCA1 forms a ubiquitylated histone-associated complex with BRCT domain-interacting
abraxas and receptor-associated protein 80 (RAP80) that plays a role in G2/M checkpoint
mediation, regulates DNA repair of DSBs,(B. Wang et al., 2007) and is a complex that
contributes to tumor suppression and genome stability.(Castillo et al., 2014)
Chk2 directly phosphorylates BRCA1 and BRAC2, and directs a preference towards HR
over NHEJ(Zannini et al., 2014) and facilitates the effector complex formation that
includes BRCA1, partner and localizer of BRCA2 (PALB2), and BRCA2.(F. Zhang et al., 2009)
The PALB2 protein effectively bridges the gap between BRCA1 and BRCA2 by binding
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directly with the N-terminus of BRCA2 and the coiled coil of BRCA1 to facilitate the
indirect binding of the two proteins.(F. Zhang et al., 2009)
2.4.3 BRCA2-associated Interactions (Figure 2-3): Deletion of SUV3 suppressor 1 (DSS1)
binds to BRCA2’s DNA binding domain (DBD) and enhances molecular stability.(J. Li et al.,
2006) PALB2 further stabilizes BRCA2 and promotes nuclear localization(Xia et al., 2006)
and is integral for the efficient operation of BRCA2-mediated repair of DSBs by aiding in
Rad51 foci localization.(Sy et al., 2009)(Xia et al., 2006)
Following DSBs, BRCA2 directly recruits Rad51 to the site of DNA damage for HRR.(H. Yang
et al., 2005)(Jensen et al., 2010)(Michael S.Y. Huen, Shirley M.H. Sy, 2013) Cyclin
dependent

kinases

(CDKs)

modulate

the

BRCA2-Rad51

interaction

through

phosphorylation of serine S3291 on the C terminal domain of BRCA2 which inhibits Rad51
binding, while decreased CDK activity under DNA damage conditions increases BRCA2Rad51 binding and increases the recombination activity of Rad51.(Esashi et al., 2005)
Rad51 binds to BRC repeats on BRCA2 (encoded by exon 11), an interaction that modulates
the choice of localization of Rad51 to either single stranded or double stranded
DNA.(Chatterjee et al., 2016) Differential BRC repeats on BRCA2 alter the binding
efficiency of Rad51 and subsequently changes the ability for the complex to form Rad51
nuclear foci.(C. F. Chen et al., 1999) Rad51, a DNA recombinase, forms a nucleoprotein
filament on ssDNA known as the presynaptic filament which catalyzes strand invasion and
homologous DNA identification, localization, and pairing which is the rate limiting step of
HRR and requires BRCA2 mediation as for efficient recombination.(Filippo et al., 2008)(Ml
et al., 2018)(Sun et al., 2020) Disruption of Rad51 activity produces a phenotypically
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analogous response to a deficiency in BRCA2, indicating that both BRCA2 and Rad51 are
critical members that act synergistically late in the HRR pathway.(Schlacher et al., 2011)
After aiding in the formation of the HR replication fork, BRCA2 further acts by stabilizing
it against nucleolytic degradation by MRE11.(Schlacher et al., 2011) Through this
degradation, MRE11 may be a major cause of instability related to embryonic lethality in
BRCA2-deficient development, as blocking MRE11’s recruitment rescues this
phenotype.(Chaudhuri et al., 2016) Genomic stability is partly maintained through this
complex DNA damage response and repair pathway, however, BRCA1 and BRCA2 also
engage in complementary participation in cell cycle regulation under both homeostatic
and stress conditions.
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Figure 2-3. Initiation of HRR. An overview of the single- and double-stranded breakinduced signalling response including BRCA1&2 participation and notable junctures at
which the cell cycle is arrested, cell fate is determined, and the choice of repair strategy
is made (Created with BioRender).
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2.5 BRCA1&2 Beyond HRR: The functions of BRCA1 and BRCA2 are distinct from each
other and include those that aide in networks conferring stability to cellular processes
and integration into the tightly controlled cell cycle.
2.5.1 Cell Cycle Regulation: Progression through the cell cycle is highly regulated, and
disruptions therein jeopardize cellular homeostasis and bring about aberrant division and
cell death, which are increasingly implicated as precipitating factors in diseases of cancer,
inflammation, and the cardiovascular system.(Zhivotovsky & Orrenius, 2010) BRCA1&2
mutation cancers are primarily viewed through the lens of impaired DNA damage repair.
However, these molecules have other important regulatory functions. Tumors of BRCA1
and BRCA2 mutation are known to occur, in part, due to failure of the cell cycle and
chromosomal

aberrations

which

can

lead

to

aneuploidy,(Tirkkonen

et

al.,

1997)(Tomlinson et al., 1998) demonstrating the existence of a regulatory role of these
molecules.
2.5.2 BRCA1 and the Cell Cycle: BRCA1 aids cell cycle regulation through its HR activity
and direct interactions with cell cycle regulatory proteins. BRCA1’s deficiency induces
genetic instability(Deng & Scott, 2000) via pleiotropy, chromosomal defects and
aneuploidy,(Paolo et al., 2014) and defects in cell cycle checkpoints.(Deng, 2006) BRCA1’s
expression and subcellular localization change in response to DNA damage and are
dependent on the cell cycle phase and phosphorylation state.(Tibbetts et al.,
2000)(Henderson, 2012) BRCA1 functions as part of the G1/S(Vaughn et al., 1996) and
intra-S checkpoints(B. Xu et al., 2002) wherein growth arrest is triggered by an abundance
of DNA damage which induces increased BRCA1 expression and triggers downstream CDK
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inhibition in a cyclin dependent kinase inhibitor 1 (p21WAF1/cip1)(Somasundaram et al.,
1997) or pRb-dependent(Aprelikova et al., 1999) manner.(Mullan et al., 2006) Gadd45 is
upregulated with DNA damage and interacts with BRCA1 to support p21/CDK1-mediated
cell cycle arrest in the G1 phase(Liebermann & Hoffman, 2018) Additionally, BRCA1
expression acts in modulating G2/M as an upstream stimulator or inhibitor of proteins
that mediate the CDC2-CyclinB mitotic kinase to suppress entry into mitosis.(MacLachlan
et al., 2000)(Biology, 1999)(Mullan et al., 2006)(Liebermann & Hoffman, 2018) A failure
in this pathway leads to an increase in chromosome defects, aneuploidy, and cell cycle
breakdown.(Hollander et al., 1999) BRCA1 also performs checkpoint modulation directly
by forming a heterodimer with BRCA1 associated ring domain 1 (BARD1) via their mutual
RING domain that obscures the nuclear export signal – ensuring nuclear
retention.(Henderson, 2005) Under stress of DNA damage, this BRCA1-BARD1
ubiquitinates cyclin B and Cdc25C, targeting them for degradation.(Shabbeer et al., 2013)
Apoptotic regulation is also performed by BRCA1 binding to ER calcium channel inositol
1,4,5-triphosphate receptor (IP3R);(Hedgepeth et al., 2015) additionally establishing the
broad governing functions of this molecule.
2.5.3 BRCA2 and the Cell Cycle: Beyond its integration in the HR pathway, BRCA2
functions to repair damaged DNA through HR integration but is also a mediator of the cell
cycle and its arrest under stress conditions. BRCA2 binds with the centrosome localization
signal (CLS) cytoplasm dynein 1; thereafter, it localizes to the centrosome where it
mediates centrosome pair cohesion, positioning, and duplication and serves as an S phase
checkpoint protein.(Malik et al., 2016)(Nakanishi et al., 2007)(Rocca et al., 2015) Without
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BRCA2 centrosome localization, there is abnormal centrosome positioning and cell
duplication, which results in multinucleate cells, potentially explaining the aneuploidy of
many BRCA2-mutation cancers.(Nakanishi et al., 2007) BRCA2 also localizes to telomeres
during the S-phase of the cell cycle to enhance telomere replication efficiency(Zimmer et
al., 2016) and its absence results in telomere instability, indicating its function in telomere
homeostasis.(Min et al., 2012)
Furthermore, BRCA2 appears to play a downstream role to Chk1 in arresting the cell cycle
in the S phase upon DNA destabilization.(Rocca et al., 2015) Following DNA damage,
BRCA2 and its HR pathway partner PALB2 are also critical G2 checkpoint
mediators.(Menzel et al., 2011) BRCA2 also operates during cytokinesis; after
phosphorylation by the mitotic polo-like kinase, PLK1, BRCA2 localizes via Filamin A to the
Flemming body at the centromere midbody, where it stimulates IIC-ring
formation.(Takaoka et al., 2014) BRCA2 mutation inhibiting PLK1 binding alters its ability
to localize(Takaoka et al., 2014) and causes a deficiency of BRCA2 at the midbody, which
provokes a delay of cytokinesis,(Jonsdottir et al., 2009) defects in cell cleavage, and
chromosomal instability,(Daniels et al., 2004) indicating the need for functional BRCA2 to
maintain this stage of the cell cycle. Insufficiency or altered localization of BRCA2 to the
midbody is another possible explanation for the chromosomal aneuploidy in many
BRCA2-related tumors.(Dupré et al., 2006) If properly localized, BRCA2 facilitates
abscission through the mediation of pro-abscission protein complexes, and if these
interactions are disrupted by a BRCA2 mutation, cancer due to cytokinetic dysregulation
may result independent of BRCA2’s ability to perform DNA damage repair.(Mondal et al.,
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2012) Altered BRCA2 expression dysregulation at the midbody due to RAS oncogene
mutation may also induce genetic instability regardless of BRCA2 functionality.(G. Yang et
al., 2013)
2.5.4 BRCA1&2, Oxidative Stress, Hypoxia, and Inflammation: Oxidizing molecules are
injurious at high cellular concentrations and can be produced from a multitude of sources,
including NADPH oxidase, mitochondrial or other cellular metabolic processes, and by
external origins; the deleterious effects of which encompass lipid, protein, and DNA
oxidation.(Weng et al., 2018) Complications of oxidative injuries are inflammation and
tissue injuries which, if chronic, are strong contributing factors in many diseases,(Mittal
et al., 2014) including atherosclerosis and cancer.(Hasselbalch, 2012)(Mittal et al., 2014)
In addition, these complications are themselves sources of reactive oxygen species (ROS)
generation.(Ohnishi et al., 2013)
BRCA1 expression is positively correlated with the antioxidant response and cellular
protection, while its deficiency results in hypersensitivity to oxidizing agents.(Bae et al.,
2004) BRCA1 stabilizes and activates nuclear factor erythroid 2-related factor 2 (Nrf2) to
reinforce its antioxidant signalling,(Gorrini et al., 2013)(Bae et al., 2004) and direct
interaction with p21 further stabilizes Nrf2 by diminishing the ubiquitination by the Kelchlike ECH-associated protein 1 (Keap1) dimer.(W. Chen et al., 2009) Nrf2 and BRCA1 are
complementary effectors against xenobiotic stress(Kang et al., 2012) and work in tandem
with p21 and p53 in the antioxidant response. Moreover, Nrf2 binding to an antioxidant
response element (ARE) directly regulates hypoxia-inducible factor 1 alpha (HIF-1a) by
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transcriptional activation.(Lacher et al., 2018) HIF-1a is crucial for regulating the hypoxic
response and BRCA1 may interact directly with HIF-1a to stabilize it in hypoxic
conditions.(Hyo et al., 2006) Most importantly, we recently demonstrated that loss of
BRCA2 enhances ROS production.(S. Singh et al., 2020)
Cellular hypoxia promotes an increase in ROS, leading to oxidative stress and exacerbating
local inflammation.(McGarry et al., 2018) Hypoxia, alongside oxidative stress and
inflammation, is a hallmark of many diseases, including cancer(Van Der Groep et al., 2008)
and atherosclerosis.(Marsch et al., 2013) Specific BRCA1 mutation may positively
influence the inflammatory cytokine response.(Woolery et al., 2015) Our group has
previously shown that loss and gain of BRCA1 exacerbates and promotes against cytokine
insults, respectively;(K. K. Singh et al., 2009) and also that BRCA1 overexpression improves
survival by reducing organ failure and inflammation in murine sepsis.(Teoh et al., 2013)
Loss of both BRCA1 and BRCA2 increases cellular sensitivity to tumor necrosis factor-alpha
(TNFα), with BRCA2 inactivation resulting in micronuclei production and a proinflammatory cytokine response, including the production of TNFα in a cyclic GMP/AMP
synthase/stimulator of interferon genes (cGAS/STING)-mediated fashion.(Heijink et al.,
10 C.E.) The myriad ways in which BRCA1&2 control cellular process and respond to
numerous cellular stresses independently and through synergistic activity indicate that
these molecules are critical for cellular homeostasis. Without their proper function, the
resulting dysregulation of cellular processes, increased inflammation and oxidative stress,
and reduced genomic stability and DNA repair capacity are disruptions that confer a
propensity towards diseases.
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2.6 BRCA1&2 in Cancer: A person’s cancer risk is contingent on their susceptibility factors,
including those that lie within their genetic makeup.(Cox, 2014) A primary example of this
is how germline mutations in the HRR pathway diminish DNA damage repair functionality,
thereby promoting carcinogenesis, as evidenced by HR-associated gene mutations
occurring in a high percentage of malignancies.(Riaz et al., 2017)
Within the scope of the HRR pathway, two of the cornerstone genes are BRCA1 and
BRCA2. Normally women face an approximately 12% risk of breast cancer development.
However, mutations in BRCA1 increase a woman’s lifetime risk of ovarian cancer to 44%
and breast cancer to 72%, while BRCA2 mutations carry a 17% and 69% lifetime risk of
ovarian and breast cancer, respectively.(Kuchenbaecker et al., 2017) Albeit, BRCA1&2
mutation is relatively rare at about 1 in 400 in North America, in certain populations such
as the Ashkenazi Jewish, germline mutation may occur in approximately 1 in 40
women.(Tennen et al., 2020) Males, however, have a lifetime risk of breast cancer of 0.1%,
which increases to 1% or 7-8% with BRCA1 or BRCA2 mutation, respectively.(Ibrahim et
al., 2018)
Approximately 5-10% percent of all breast and 10-15% of all ovarian cancers are due to
BRCA1&2 mutation and at an earlier onset than sporadic cancers.(Mehrgou &
Akouchekian, 2016) Both breast and ovarian cancer dispositions are dependent on where
within the sequences of each genes the mutation emerges; specific site mutations in
either BRCA1 or BRCA2 have been identified to predispose significantly towards either
breast or ovarian cancer.(Rebbeck et al., 2015)(Thompson & Easton, 2002)
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Due to the many possible mutations that may differentially affect the function of
BRCA1&2, breast and other cancer penetrance vary with population and other statuses,
including any prophylactic measures as well as age, child-bearing history, the parental
origin of germline mutation, and comorbidities – particularly those that exacerbate DNA
damage.(Kramer et al., 2005)(Bernholtz et al., 2011)(Friebel et al., 2014) Analysis of
penetrance demonstrated that among families with a strong history of breast cancer, 52%
were BRCA1 positive and 32% BRCA2 positive and while breast-ovarian cancer is highly
predictive of a BRCA1 mutation, families with a male and female history of breast cancer
exhibit a high propensity towards BRCA2 mutation.(Ford et al., 1998)
Beyond breast and ovarian cancers, BRCA1/2 mutation predisposes carriers to cancer of
the digestive system,(Cavanagh & Rogers, 2015) prostate,(Cavanagh & Rogers, 2015)
fallopian tube, peritoneum, and possibly melanomas(Ginsburg et al., 2010)(Gumaste et
al., 2015) and other cancers.(Mersch et al., 2015)(B., 2005) However, BRCA1/2 mutations
are benign in many cancers, and the full mechanism for their specificity is still being
elucidated.(Cullinane et al., 2020)(Jonsson et al., 2019)
Cancer-type rates, while unilaterally heightened for men and women, exhibit sex and
tissue specificity due to hormone-responsive gene expression-related stress(X. Zhang et
al., 2017) and modulation of BRCA1&2 leading to differential cellular development and
proliferation.(Van Asperen et al., 2005)(Rajan et al., 1997) Proliferative regulation by BRCA2
of cancer cells may further exacerbate tumorigenesis in the case of BRCA2 mutation.(S. C. Wang
et al., 2002) Moreover, low overall BRCA2 expression level is independently associated
with cancer severity in sporadic breast cancers(Sarkar, 2018), and higher cytoplasmic
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expression of BRCA1&2 is indicative of better outcomes in cancers of the digestive system,
whereas BRCA1 nuclear expression is correlated with poor survival rates.(G. H. Wang et
al., 2018)
BRCA1&2 do not act only within the scope of DNA damage repair, but instead function
along a complex pathway of homologous recombination, so unsurprisingly, loss-offunction mutations in molecules along this common pathway may also result in cancer
predisposition by failure to mitigate DNA damage leading to accumulation and mutation.
2.7 Homologous Recombination Repair Pathway and Cancer: Increased cancer risks have
been observed with HR molecule mutations such as in BARD1, BRCA1’s N terminal
interactor, which is associated with breast cancer;(De Brakeleer et al., 2010)(Ratajska et
al., 2012) abraxas which has known tumor suppressor functions;(Castillo et al., 2014) DSS1
that acts with BRCA2 to confer stability to the protein such that mutations in it cause
hypersensitivity to DNA damage and could be implicated in breast and ovarian cancer;(J.
Li et al., 2006) and PALB2 mutations which impair its operation with BRCA2 leading to a
failure to properly recruit Rad51 to the site of DNA damage.(Sy et al., 2009)(Xia et al.,
2006) While this is not an exhaustive list, other genes that have been implicated in
carcinogenesis range from DNA damage sensors, mediators, and effectors and include
ATM,(Choi et al., 2016) BRCA1 interacting helicase 1 (BRIP1),(Weber-Lassalle et al., 2018)
NSB1,(Lamarche et al., 2010) and H2AX.(Celeste et al., 2003)
If proteins critical for the efficient function of the HR repair pathway have their function
hindered or lost, a common effect is the promotion of carcinogenesis. However, the
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development and proliferation of cancerous cells often require loss of the synergistic
tumor suppression capacity that is conferred by molecules like p53.(Jonkers et al., 2001)
p53 is a tumor suppressor gene that responds to DNA damage, signals cell cycle arrest,
and can also initiate apoptosis in a context-dependent manner.(Efeyan & Serrano,
2007)(Perri et al., 2016)(Agrawal et al., 2018)
2.8 Atherosclerosis and Endothelial Dysfunction: The endothelium (Figure 2-4) is
comprised of a single layer of cells lining blood vessels that exhibit tissue- and organ-type
heterogeneity(Marcu et al., n.d.)(Rafii, 2018) with greatly differing tissue-dependent
turnover rates(Hobson & Denekamp, 1984)(Heart et al., 2015) and composition.(Gehr,
1982)(Bowden, 1981) Endothelial cells are the direct interface between the blood and
other vascular cells and play a direct role in maintaining vascular smooth muscle cell
(VSMC) homeostasis in healthy vascular tissue.(Microrna- et al., 2013)
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Viscous blood flowing through the varied and branching geometry of the vasculature
subjects the endothelium to differential hemodynamic forces, including wall shear stress
and hydrostatic pressure.(Davies, 2009) Branch points and curved regions are areas of
turbulence and reduced laminar flow; these areas are prone to endothelial injury,
cholesterol deposition, and are vulnerable to developing atherosclerotic lesions(Michael
A. Gimbrone Jr., 2013) due to reduced shear stress.(Foteinos et al., 2008)(Tricot et al.,
2000)
In atherosclerosis (Figure 2-5), endothelial cells undergo apoptosis, senescence, and
release stimulus-dependent, pro-inflammatory cytokines.(Suzuki et al., 2013) Cytokines
recruit leukocytes to the endothelium, where they become plaque constituents and
participate in endothelial stress. As atherosclerosis progresses, arterial narrowing results
in even further shear stress reduction in downstream plaque regions, leading to high rates
of endothelial apoptosis and may spur plaque erosion and thrombus.(Tricot et al.,
2000)(Kockx, 1998)
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(V, VI) As atherosclerosis progresses, the intimal lipid core is formed by constituents
including cholesterol crystals, cellular debris, lipid-laden macrophages, SMCs, and
connective tissue. (VI) Intimal and lipid core expansion exacerbated by increasing shear
stress as the lumen narrows may cause fibrous cap rupture and the release of clot-forming
plaque. Clinical outcomes of such a thrombus include peripheral artery disease,
myocardial infarction, and stroke. (Created in BioRender)

2.9 DNA Damage and Repair in Cardiovascular System: A persistent source of DNA
damage is the generation of reactive oxygen species (ROS), including hydroxyl radicals,
hydrogen peroxide, singlet oxygen, and peroxynitrite, which are generated throughout
the course of cell metabolism, or by exogenous sources such as drugs, sunlight, and
ionizing radiation.(Hakem, 2008) ROS interact with DNA, causing nucleotide alterations,
and importantly, they have the capacity to break the DNA chain resulting in single- and
double-stranded breaks.(MacLachlan et al., 2000)(Altieri et al., 2008) Cells under
oxidative stress and undergoing accelerated DNA damage experience dysregulation of
critical cellular processes, arrest of the cell cycle, cell death, and mutations – leading to
phenotypic abnormalities such as accelerated aging, cancer development, cardiovascular
diseases, and pathologies stemming from genomic instability.(Errico et al., 2021)(Deng &
Scott, 2000)
2.9.1 DNA damage and Atherosclerosis: DNA damage levels are positively correlated with
the extent of atherosclerosis and are an integral component of coronary artery
disease.(Botto et al., 2001) VSMCs constitute a significant portion of atherosclerotic
regions and may undergo phenotype switching via trans-differentiation into macrophagelike cells, foam cells, and cells that produce the extracellular matrix of the fibrous cap.(Feil
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et al., 2014)(Bennett et al., 2016) Given their ubiquity in atherosclerotic plaque, VSMC
stability is integral to stable lesions, while high rates of apoptosis induced by DNA damage
destabilizes plaque, leading to rupture and the consequential atherosclerotic cascade
culminating in vessel occlusion and ischemia.(Clarke & Bennett, 2007)(Bennett et al.,
1995)(Gray et al., 2015) Moreover, the increased oxidative stress in atherosclerotic
VSMCs compromises these cells’ DNA damage repair pathways, (Shah et al., 2018) and
causes RAS protein-induced VSMC senescence and inflammation; all of which accelerate
atherosclerosis.(Minamino et al., 2003) Endothelial cells, which line the inner-most layer
of every blood vessel, play an important role in the pathogenesis of atherosclerosis.(M. Li
et al., 2018)
We have previously demonstrated that accumulation of DNA damage in endothelial cells
exacerbates endothelial dysfunction and apoptosis.(S. Singh et al., 2020) DNA damage is
found ubiquitously in atherosclerotic patients, including in circulating cells, which exhibit
a high micronuclei index correlating with CAD severity,(Botto et al., 2001) as well as in the
mitochondrial DNA (mtDNA) within atherosclerotic regions – indicating an extensive link
between DNA damage and atherogenesis.
2.9.2 mtDNA Damage and Atherosclerosis: Mitochondria are responsible for oxidative
phosphorylation, a by-product of which is the generation of ROS. Mitochondrial DNA
(mtDNA) exists as a single circular chromosome, and DNA damage to it is found
extensively throughout the vessel walls and circulating cells of atherosclerotic mice.
mtDNA damage is associated with greater CVD risk.(E. Yu et al., 2013) Evidence supports
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the link between mtDNA damage and atherogenesis and has provided elucidation of its
role in inflammation, apoptosis, and oxidative stress.(E. P. K. Yu & Bennett, 2014) mtDNA
damage results in mtDNA mutations,(Mohamed et al., 2004) which cause mitochondrial
metabolic dysfunction in VSMCs and, to an even greater extent, the endothelial cells of
atherosclerotic patients(Ballinger et al., 2000) due to impaired function of genes that
support the electron transport chain and code for ribosomes and transfer RNA
(tRNA).(Volobueva et al., 2019) ROS-induced mtDNA damage to vascular tissues may thus
be an early initiating factor in atherogenesis that compromises the metabolic process and
perturbs mitochondrial lipids, proteins, and DNA, all of which culminate in vascular
dysfunction and disease. mtDNA-related disruptions have been linked to defects and
lesions of the vasculature, and are congruent with the atherosclerotic hallmarks of
endothelial dysfunction and inflammation.(Ballinger et al., 2002)
2.10 DNA Modification and Atherosclerosis: DNA and mtDNA damage are readily
apparent among the atherosclerotic milieus. However, CVD’s progression and severity
may also be influenced by genetic and epigenetic modifications to DNA, including single
nucleotide polymorphisms (SNPs), methylation states, and dysregulated telomere length.
2.10.1 Genetic Associations and Epigenetic Regulation in Atherosclerosis: Genome-wide
association analysis has revealed a connection between SNPs and subclinical CVD,
including increased coronary artery calcium and greater carotid intimal media
thickness.(Vargas et al., 2016) SNP functional variants associated with atherosclerosis risk
have been found in Caucasian, Hispanic, and Chinese people.(Howard et al., 2013)(Chu et
al., 2017)(Liu et al., 2013) Furthermore, quantitative microarray profiling of
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atherosclerotic patients has detected differential methylation of CpG-sites in both the
aortic and carotid arteries in humans, as well as in animal models.(Nazarenko et al.,
2011)(Aavik et al., 2019)(Wierda et al., 2015)(Papers et al., 2004) Interestingly, the BRCA2
locus has been verified to contain alterations associated with increased coronary artery
disease and stroke.(Miao et al., 2017)
2.10.2 Telomere Shortening and Atherosclerosis: Differential genomic modifications in
atherosclerosis have been observed in telomeric shortening rates. Telomeres naturally
exhibit progressive attrition upon each round of cellular division; however, premature
shortening exists as one facet of many pathologies, including metabolic syndrome and
those involving CVD.(Obana et al., 2003)(Salpea & Humphries, 2010) Telomere
dysfunction occurs alongside activation of the DNA damage response pathway,(Takai et
al., 2003) which exhibits continuous activation at telomere damage sites that resist repair,
thus initiating the cell into senescence irrespective of otherwise sufficient telomere
length.(Fumagalli et al., 2012) Telomeric shortening is associated with increased oxidative
stress, cellular senescence, and DNA damage in VSMCs.(Sampson et al., 2001)(Matthews
et al., 2006) VSMC senescence, activated along DDR, p21 and p16 pathways, is a known
exacerbator of CVD.(Andreassi, 2008) VSMC senescence may be mitigated through statin
treatment that induces an increase in DNA damage repair and NSB1 stabilization, thereby
preventing the attrition of telomeres.(Mahmoudi et al., 2008) Exacerbators of CVD
associated with shorter telomere length include age, smoking, and high levels of lowdensity lipoprotein (LDL) cholesterol(Koriath et al., 2019) – co-risk factors with cancer
(Figure 2-6).
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2.11 BRCA1&2 in Cardiovascular Diseases: Cancer risks for BRCA1&2 mutation carriers
are well defined; however, significantly higher non-neoplastic morbidities have been
reported in BRCA1&2 mutation-positive cancer patients.(Mai et al., 2009) Moreover,
negative effects on the cardiovascular system may occur independently of cancer; for
those with cancer, complications be compounded due to a potentially increased BRCA
mutation-related sensitivity to CVD.
2.11.1 Intersections Between Cardiovascular Disease and Cancer

Figure 2-6. Cardio-oncological Overlaps: common risk factors and links between
cardiovascular disease and cancer.
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2.11.2 Risk Reducing Salpingo-oophorectomy and Mastectomy and CVD: BRCA1/2
mutation carriers may opt to protect themselves against the high likelihood of cancer by
undergoing the prophylactic surgeries of risk-reducing salpingo-oophorectomy (RRSO) or
mastectomy (RRM). While these surgeries confer a high degree of protection against
cancer development,(Kramer et al., 2005) they are associated with increased non-cancer
mortality in BRCA-positive women.(Anna Öfverholm, Zakaria Einbeigi, Antonia Wigermo,
2019) This phenomenon may be the result of cardiovascular complications due to early
menopause. The hormone and lipid changes due to natural menopause are associated
with a higher CVD predisposition,(Kat et al., 2017)(Fairweather, 2014) an effect
exaggerated by more acute changes, and a high incidence of metabolic syndrome,
particularly in those who have undergone RRSO, further exacerbating the rate of type II
diabetes, heart disease, and stroke,(Dørum et al., 2008) due to arterial stiffening,(Abbas
et al., 2018) hyperlipidemia, and hypertension(Cohen et al., 2012) in these patients. If
below the age of 50, RRSO recipients also exhibit a higher risk of osteoporosis,(Cohen et
al., 2012) a syndrome that overlaps with CVD in risk factors and may be implicated in CVD
development.(Cauley & Cauley, 2008)
2.11.3 Anthracyclines and Cardiotoxicity: After cancer diagnosis, treatment options are
often centered around surgery and chemotherapeutics, such as a class of drugs known as
anthracyclines.(Tan et al., 2017) Anthracyclines are genotoxic as they intercalate into the
DNA minor grooves and also pose a high risk to cardiovascular health.(Schmidt et al.,
2016)(Aleman et al., 2007)(Belt-dusebout et al., 2021) Anthracyclines are a known factor
in the development of congestive heart failure(Lefrak, A., Pit’ha, J., Rosenheim, S., 1973)
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and cardiomyopathy.(Blanco et al., 2021) Children, in particular, are subjected to a high
risk of these deleterious effects, (Mulrooney & Yeazel, 2009) which may be intensified by
the use of radiation therapy(Mueller et al., 2013); these complications may not be
apparent until many years after treatment completion.(Skitch et al., 2017)
An analysis of BRCA mutation carriers supports the idea that these individuals are indeed
at an increased risk of cardiotoxicity and non-neoplastic mortality due to anthracycline
treatment,(Sajjad et al., 2017)but this connection is not always observed.(Pearson et al.,
2017) The risk could be partly explained by the marked increase in cardiomyocyte
apoptosis under anthracycline stress and BRCA2-deficient conditions.(K. K. Singh et al.,
2012) Moreover, hypertension is a common comorbidity in BRCA1&2-positive patients
with

breast

cancer,

leaving

these

patients

particularly

vulnerable

to

cardiotoxicity.(Antone et al., 2017)
2.11.4 Cardiovascular Disease Intrinsic Risk with BRCA1&2 Mutation: The ubiquitous
nature of DNA damage occurring alongside cardiovascular diseases, such as
atherosclerosis, has spurred interest in the study of an intrinsic risk of CVD for BRCA1&2
mutation carriers. Hallmarks of atherosclerosis include oxidative stress, cellular
dysregulation, and DNA damage, all of which are known to be intensified under a BRCA
deficit. As previously discussed, differential methylation is a hallmark of atherosclerotic
regions, and BRCA1 is known to be affected alongside CVD with methylation changes that
occur with subclinical atherosclerosis.(Geoffrey et al., 2017) Further, the study of SNPs as
potential biomarkers for disease revealed specific BRCA2 variants to be associated with
CVD incidence,(Zbuk et al., 2012)(Miao et al., 2017) and a large-scale meta-analysis
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identified an association between BRCA2 SNP variants and increased LDL
cholesterol.(Asselbergs et al., 2012)
Lipid dysregulation is a hallmark of cardiovascular disease and cancer, and the proper
modulation of lipogenesis is important for disease protection. BRCA1 affects this by acetyl
coenzyme A carboxylase binding(Shen & Tong, 2008) – stabilizing its phosphorylation site
– thereby inhibiting increased lipogenesis(Moreau et al., 2006) and insulin
signalling.(Jackson et al., 2014) Further evidence exists for lipid(Genetic et al.,
2015)(Oliverio et al., 2020) and metabolic(Oliverio et al., 2020) dysregulation in both
BRCA1&2 mutation carriers, suggesting the existence of a metabolically active role carried
out by these genes and their potentially protective role against a proatherogenic lipid
profile.
2.11.4.1 BRCA1&2 in the Heart: BRCA1 is shown to provide cardio-protective qualities, as
its loss in cardiomyocytes exacerbates myocardial infarction-induced heart failure;(Shukla
et al., 2011) cardiomyocyte-specific loss of BRCA1 is also associated with glucose and
fatty-acid metabolic changes, resulting in an energy-starved heart.(K. K. Singh et al., 2013)
This loss further leads to DSB accumulation; apoptosis due to activation of the proapoptotic p53; and eventual cardiac failure as a result of impaired cardiac
remodelling.(Shukla et al., 2011) Inefficient or reduced expression of BRCA1 may
therefore present as cardiomyocyte stress and lead to a higher incidence of cardiac failure
under ischaemic stress in BRCA1 mutation carriers. Association between heart failure and
BRCA1 is also demonstrated by a significantly increased expression of BRCA1 observed in
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failing human heart/cardiomyocytes, arguably to promote DNA damage repair and
survival in the stressed heart.(Shukla et al., 2011) Interestingly, cardiomyocyte-specific
loss of BRCA2 also promotes heart failure following genotoxic stress.(Cite J Biol Chem,
2012) Taken together, it appears that BRCA1, BRCA2, and DNA damage repair
mechanisms are cardioprotective in nature and loss of any of these leads to adverse
cardiac remodelling under stress.
2.11.4.2 BRCA1&2 in Thrombosis: The most critical clinical outcome of atherosclerosis is
thrombogenic plaque rupture and release, which quickly progresses to clot formation and
ischemia. BRCA1 mutation carriers exhibit altered expression of proteins known to
participate in thrombogenesis, including elevated levels of fibrinogen gamma chain
isotypes 2 and 3,(Custodio et al., 2012) which, interestingly, are known to be associated
with poor outcomes in some cancers.(J. M. Jones et al., 2006)(Qingqu Guo et al., 2009)
Similarly, BRCA2 mutation results in expression alterations to thrombo-coagulating
related proteins, not dependent on breast cancer development.(Perez-segura et al., 2016)
Additionally, independent of carcinogenesis, those with a BRCA gene mutation are at
increased risk of pulmonary embolism after abdominal flab breast construction
surgery(Timman & Ph, 2013). This shift to a potentially pro-thrombotic plasma
environment may leave BRCA1&2 mutation carriers particularly vulnerable to plaque
rupture, thrombosis, thromboembolism, and vessel occlusion, especially concerning for
mutation carriers who develop atherosclerosis, even if cancer-free.
2.11.4.3 BRCA1&2 in the Vasculature: Cellular regulation is essential for the impedance
of atherogenesis at the level of inflammatory cells and, in particular, the cells of the
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vasculature, which include vascular smooth muscle cells and endothelial cells.(Foteinos
et al., 2008; Michael A. Gimbrone Jr., 2013; Microrna- et al., 2013)(M. Li et al., 2018)
BRCA1&2 act independently to mediate genomic- and cell-stability,(Roy et al., 2012) thus
may be integral in hindering atherosclerotic progression via these mechanisms.
2.11.4.4 BRCA1&2 in the Vascular Smooth Muscle Cells: Vascular smooth muscle cells
are structurally significant and are integral to vascular constriction and relaxation. They
are also responsible for proliferative and vascular remodelling under cyclic and
hypotensive conditions. BRCA1 has been shown to have an effect on protecting VSMCs
by mitigating oxidative stress through NADPH Nox1-dependent ROS production
inhibition.(Lovren et al., 2014) Moreover, hypertensive rats with induced BRCA1
expression via adenovirus exhibit vascular protection due to decreased blood pressure
and ROS production.(Chessex et al., 2013)
2.11.4.5 BRCA in the Endothelium, Endothelial Dysfunction, and Atherosclerosis: A
cohort of male BRCA1&2 mutation carriers was observed with significantly higher levels
of endothelial progenitor cells when measured as a fraction of CD34+/VEGF or
CD133+/VEGF, suggesting a state of accumulated endothelial damage and indicating
increased cardiovascular risk in BRCA mutation carriers in addition to their established
cancer susceptibility.(Witberg et al., 2019) Our group previously demonstrated that
protection against atherosclerosis was provided by BRCA1 through upregulation of
endothelial nitric oxide synthase and attenuated ROS production, inflammation, and
apoptosis. In addition, limited atherogenesis, and improved capillary density was
observed after ischemic injury.(K. K. Singh et al., 2009) Similarly, BRCA2 protected
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endothelial cells under oxidized LDL (oxLDL)-induced oxidative stress; BRCA2 loss was
associated with a reduction in DNA damage repair capacity and an increase in apoptosis
in vitro.(S. Singh et al., 2020) These findings have demonstrated an important role for
BRCA1 and BRCA2 in endothelial regulation and suggest a protective function against
atherosclerosis.
In atherosclerosis, the oxidative environment causes DNA damage and alteration to the
vasculature. To blunt these effects, endothelial cells produce proteins to repair DNA
damage and maintain stability. As previously discussed, the breast cancer susceptibility
genes 1 and 2 represent a major component of error-free HR and confer stability to many
cell types. The BRCA1/2-integrated HR pathway broadly mitigates the deleterious effects
of endothelial dysfunction, including altered DNA damage, apoptosis, inflammation, and
proliferation. However, only recently has there been an appreciation for BRCA2-induced
cardioprotective and anti-atherogenic roles.
2.12 Thesis Motivation: There is now extensive evidence for DNA damage and alterations
occurring within the atherosclerotic milieu. As the evidence mounts, a closer look at how
DNA damage relates to the cellular disturbances that beget atherosclerosis may open new
therapeutic avenues. Moreover, DNA damage and markers of functional or dysfunctional
repair may be used as subclinical diagnostic biomarkers, allowing for enhanced screening
in vulnerable populations.
However, DNA damage repair proteins are not autonomous actors apart from other
cellular processes. They often interact with many partners, forming complexes that have
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the regulatory capacity to maintain cellular stability on multiple levels. Therefore, the
study of these proteins and their interconnected pathways is likely to bring about a richer
understanding of their role in DNA damage repair, aging, and diseases, including those of
the cardiovascular system.
Pioneering work on assessing the role of the HR proteins BRCA1 and BRCA2 has already
provided evidence for their likely protective quality of maintaining vascular and cardiac
health. Yet, further in vivo studies and translational research should be carried out to
confirm the magnitude of their involvement in CVD. Carriers of mutations in these genes
may very well be more susceptible to or have a higher, yet unrecognized, independent
risk of developing cardiovascular disease. Beyond these efforts, an expansive look into
the functional HR pathway proteins may provide insight into other culprits of cellular
dysregulation and CVD initiation.
Mutation in BRCA1 or BRCA2 increases the risk of breast cancer and both BRCA1&2 play
an integral but non-redundant role in HRR pathway. However, it is important to note that
BRCA1 and BRCA2 are structurally distinct proteins; they interact with different protein
partners, play a non-redundant role in different stages of genome protection, have
different cancer predisposition rates, lifetime risk, estimated frequency, and types and
characteristics of cancers. (Roy et al., 2012) In contrast to BRCA1, BRCA2 is also associated
with lipid regulation and inflammation. (Genetic et al., 2015)(Oliverio et al.,
2020)(Woolery et al., 2015) Moreover, BRCA2 gene resides on the human chromosome
13q12.3, a region linked to CVDs in humans. (Miao et al., 2017)(Jie et al., 2013) It is also
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important to note that BRCA2, but not BRCA1 expression, is significantly affected by oxLDL
treatment in endothelial cells.(S. Singh et al., 2020) Therefore, identifying mechanisms
linked to BRCA2 would provide new and distinct information related to BRCA2’s role in
the endothelium, and how BRCA2 may pertain to cardiovascular health and disease. In
summary, the BRCA2 protein responds to DNA damage by participating in complex
cellular pathways of DNA damage repair. (Roy et al., 2012) BRCA2 provides genome
stability and limits apoptosis, whereas mutations in BRCA2 cause breast and ovarian
cancer.(Roy et al., 2012) In humans, potential higher incidence of non-neoplastic deaths
have been observed in BRCA2-mutants,(Mai et al., 2009) and BRCA2 SNPs are correlated
with plasma-lipid levels,(Asselbergs et al., 2012) and deregulation of both lipid and
metabolites in BRCA2-mutants.(Genetic et al., 2015) Loss of endothelial BRCA2
exacerbates oxLDL-induced endothelial dysfunction.(S. Singh et al., 2020) Abnormal lipid
metabolism and endothelial dysfunction are the central pathways leading to
atherosclerosis;(M. Li et al., 2018) however, BRCA2’s role within the scope of endothelial
dysfunction and atherosclerosis remains unknown.
Accordingly, the goal of this thesis is to evaluate the pathophysiological role of endothelial
BRCA2 using a clinically relevant in vivo model of atherosclerosis. Specifically, we
hypothesize that endothelial cell-specific loss of BRCA2 augments DNA damage, apoptosis,
and endothelial dysfunction, and thereby exacerbates atherosclerosis.
My thesis will delineate a critical and novel role of BRCA2 limiting endothelial cell
apoptosis and dysfunction. In addition to identifying a potentially new therapeutic target,
our data may point towards a heightened susceptibility of BRCA2 mutation carriers
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toward atherosclerosis and other CVDs, thereby providing an evidence-based framework
for future studies to support translational research applications.
2.13 Thesis Objectives: This thesis is conducted to determine the pathophysiological role
of BRCA2 using loss-of-function approach with the following objectives.
(i)

Generate and characterize an endothelial cell-specific BRCA2 knockout mouse
utilizing Cre-LoxP technology.

(ii)

Generate and characterize endothelial cell-specific BRCA2 knockout mouse on
ApoE-/- background and evaluate high-fat diet-induced atherosclerosis.
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Chapter 3. Methods
3.1 Animal Studies: Studies herein were approved by the Western University Animal Care
Committee and all associated animal procedures adhered to the guidelines set out by the
Canadian Council on Animal Care. Animal endpoints were determined pursuant to
approved experimental parameters and early endpoints by veterinarian recommendation.
Experiments were performed on mice aged 8 weeks and older which were housed in a
sterile, environment-controlled facility (40-60% humidity, 22-24°C temperature, cage
ventilation with HEPA filtration) on a 12hr light/dark cycle. Each cage housed up to four
mice and were supplied with reverse osmosis water chlorinated to 2-3ppm ad libitum,
and the mice were maintained on an excess of standard laboratory chow-type diet (NIH31, Cat# 7013, Open Formula Mouse/Rat diet, irradiated – Envigo) or experimental, highfat diet (“Western” purified atherogenic diet TD.88137, irradiated – Envigo).
3.2 Generation of Single Knockout Mice: Endothelial cell-specific BRCA2 knockout was
achieved by virtue of the Cre-LoxP system of tissue-specific gene excision (Figure 3-1, B).
Mice homozygous for the exon 11 floxed BRCA2 allele with a BALB/cJ background (NCI;
Strain #: 01XB9; Common name: Brca2 floxed; Strain Nomenclature: STOCK
Brca2tm1Brn/Nci) were crossed with mice hemizygous for Cre-recombinase expression
under control of the vascular endothelial (VE) Cadherin 5 promoter and on a C57BL/6J
background (The Jackson Laboratory; Stock #: 006137; Common Name: VE-Cadherin-Cre
(VE-CRE; Strain Nomenclature: B6.FVB-Tg(Cdh5-cre)7Mlia/J). Breeding was performed in
accordance with the schematic in Figure 3-1, A. Heirs from the crossing of the two
described strains were bred to generate single knockout mice that are homozygous
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BRCA2 floxed and hemizygous for VE-Cre: BRCA2fl/fl;VE-Cretg/- (BRCA2endo). Heterozygote
knockout BRCA2fl/wt;VE-Cretg/- (BRCA2het) were used for to gauge the dose dependency of
BRCA2-loss in endothelial cells. Wildtype littermates – BRCA2fl/fl;VE-Cre-/- and
BRCA2fl/wt;VE-Cre-/- and BRCA2wt/wt;VE-Cretg/- (BRCA2wt) – were used as controls.
Wherever possible, the latter Cre+ wildtype was analyzed independently, then if no
differences were observed, all wildtype mice were pooled together. Functional and
molecular assays were utilized to elucidate the baseline effect of the loss of function of
endothelial cell specific BRCA2 in young (8–16-week-old) mice to ascertain the emergence
of early developmental effects. These mice are inbred for multiple generations and the
strain is currently being maintained by breeders.
A)

B)
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Figure 3-1. Breeding Schematic and the Cre-LoxP System. (A) Cre-LoxP method-based
breeding strategy for generating endothelial cell specific BRCA2 knockout mice
(BRCA2endo). (B) Cre-LoxP system schematic representation at the genomic level
illustrating Cre-mediated, BRCA2 exon 11 deletion.
3.3 Generation of Double Knockout Mice: Generation of the in vivo model of
atherosclerosis was achieved by crossing the existing BRCA2endo strain with mice
homozygous for an ApoE loss of function mutation on a C57BL/6J background (The
Jackson Laboratory; Stock #: 002052; Common Name: ApoE KO; Strain Nomenclature:
B6.129P2-Apoetm1Unc/J). ApoE is a requisite molecule for hepatic LDL receptor-mediated
lipoprotein clearance, and its deficiency results in high levels of circulating
cholesterol.(Curtiss, 2000) These mice are well described for their propensity towards
plaque development and vascular lesions under high fat diet and are a standard model
for atherosclerotic studies.(Curtiss, 2000)(Greenow et al., 2005) The progenies of this
crossing (BRCA2fl/+;ApoE-/+;VE-Cretg/- X BRCA2fl/+;ApoE-/+;VE-Cre-/-) were interbred,
resulting in the generation of the double knockout experimental target genotype
(BRCA2fl/fl;ApoE-/-;VE-Cretg/-) (Figure 3-2). Both this double knockout and their wildtype
control littermates were fed a high-fat diet starting at 10 weeks of age. Monitoring of
these mice was done weekly for gross phenotype, and they were weighed at intervals of
2 weeks. After 8, 12, and 16 weeks of high fat diet, tissues from these mice were collected
for RNA, protein, and histological analysis and the aortas and aortic roots of these mice
were assessed for atherosclerotic magnitude. This strain is currently being maintained by
breeders.
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Figure 3-2. Breeding Schematic for Double Knockout Mouse. Previously generated
BRCA2endo single knockout mice are bred in conjunction with ApoE-/- mice to generate
ApoE-/-;BRCA2endo double knockout mice.

3.4 Genotyping: The WISNET ADVANCEDTM DNA fast extract kit was used to extract
genomic DNA from ear clippings pursuant to the manufacturers recommended guidelines.
The supernatant of this extract was used in conjunction with primers for BRCA2, VE-Cre,
or the ApoE mutant gene where appropriate. Amplification of these genes was performed
via polymerase chain reaction using 2x HS-Red Taq mix, and the product was run on 2%
agarose gel formed with 1x Tris-Borate-EDTA (TBE) or Tris-acetate-EDTA (TAE) buffer
containing Red Safe (FroggaBio, Cat#21141) for visualization with UV transillumination
with the LICOR Odyssey FC imaging system.
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3.5 Tissue Collection: Mice were placed under deep anesthesia using bell jar isoflurane
method. Mice were anchored at their extremities in a supine position under maintenance
anesthesia. Fur and skin were removed, and incisions were made into the parietal
peritoneum for abdominal access and further lateral cuts were made into the peritoneum
and bilateral ascending cuts were made along the ribcage. Tissue forceps were used to
secure the xyphoid process and peel back the sternum and ribcage to access the thoracic
cavity. Lateral or descending cuts along the parietal peritoneum were performed to
further open the abdominal cavity as necessary for organ and abdominal aorta collection.
Exsanguination was performed via right ventricle cardiac puncture using a 27-gauge
needle. Perfused and non-perfused tissue collection was performed based on the needs
of individual experiments as further noted. The head was separated and placed on ice
while organs were collected including the heart, aorta, lung, liver, kidney, and spleen,
followed by the brain. Tissues were washed in 1x cold PBS and immediately flash frozen
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in liquid nitrogen then stored in -80°C for RNA and protein extraction or placed in 4% PFA
or 10% formalin for immunohistochemical work.
3.6 RNA Extraction: Whole tissues were snap frozen in liquid nitrogen and triturated using
a mortar and pestle. Tissues were homogenized in 1mL Trizol (ambion, Cat# 15596018,
Lot# 318303) and allowed to incubate at room temperature for 5-10 minutes then on ice
for another 15 minutes. Phase separation was performed by adding 200μL of chloroform
and vigorously shaken by hand for 15 seconds followed by 3-minute incubation at RT
before centrifuging at 12,000 RCF and 4°C for 15 minutes. The clear, upper RNA phase
was transferred to a new RNase free tube. RNA precipitation was performed by adding
500μL of isopropyl alcohol and inverted 5 times before incubating for 10 minutes at RT
and centrifuging at 12,000 RCF at 4°C for 10 minutes to pellet the RNA. The supernatant
was poured off and the pellet was left to partially air dry before adding 1mL of 75%
ethanol then lightly vortexed to wash the pellet prior to centrifuging at 7,500 RCF at 4°C
for 5 minutes; this step is repeated once if the pellet is visible. The ethanol is poured off
and the pellet is allowed to partially air dry and the RNA is subsequently dissolved in 2540μL of DEPC water and reconstituted with a pipette then vortexed and 65°C incubation
for 3 minutes, followed by 2-3 minutes on ice, high speed vortex for 5 seconds, centrifuge,
and storage in -80°C. This method was used for RNA isolation unless otherwise indicated.
3.7 cDNA Synthesis: cDNA synthesis was performed using QIAGEN’s QuantiTect reverse
transcription kit (Cat# 205311) and pursuant to the recommended guidelines using 1μg
RNA/sample and Eppendorf PCR Mastercycler. Samples were stored in -20°C.
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3.7.1 PCR on Lung cDNA and Agarose Gel Electrophoresis: Whole lung RNA was extracted
followed by cDNA synthesis as described. PCR amplification was carried out using 12.5μL
2x HS-Red Taq 2-6μL cDNA extracted from BRCA2endo, BRCA2het, and BRCA2WT samples;
with primers for BRCA2 exon 10F/14R, BRCA2 exon 11F/11R, and GAPDH F/R at a final
concentration of 0.4μM per primer; and balanced to 25μL with DEPC H2O on Eppendorf
PCR Mastercycler. 10μL were loaded into wells of 2% agarose (VWR Life Science Agarose
I, Cat# 0710-500g, Lot# 18K2756730) gel and run at 60V for 1-2hrs until desired resolution
was reached.
3.7.2 Real-time PCR or Quantitative (q)PCR: Whole lung tissue RNA was extracted
followed by cDNA synthesis as described. qPCR was effectuated with SYBR Green master
mix on the Quantstudio 3TM with standard protocol using primers indicated in Table 3-2.

Table 3-2

PCR reactions consisted of 5μL SYBR, 0.5μM final concentration of forward and reverse
primers, 2-3μL cDNA (synthesized from 1μg RNA and diluted 1:5) and balanced to 10μL
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with DEPC H2O. Each sample and primer combination were performed in triplicates and
fold-change expression was calculated on triplicate means by the delta-delta CT method.
Statistical analysis was carried out in Graphpad Prism using ordinary one-way ANOVA with
Tukey’s post-hoc.
3.8 Immunoblotting: Tissues or isolated cells were extracted as previously described.
Tissues were mechanically broken down either using a mortar and pestle and liquid
nitrogen or a homogenizer. Homogenized tissues or cells were suspended in ice-cold RIPA
(Fisher Scientific, Cat# J62524, Lot# U14F514) buffer with protease inhibitor (PI) cocktail
and incubated on ice for 30 minutes . Samples were centrifuged at 15,000 RCF and 4°C for
15 minutes and the supernatant was extracted for further processing. Total protein was
quantified in triplicates by standard Bradford assay using Coomassie Plus
(ThermoScientific, Cat# 1856210, Lot# UC277715) reagent and absorbance at 595nm was
measured by microplate reader (Bio-Rad iMark Microplate Reader).
Protein samples were prepared and normalized to 5-50μg. Loading sample preparation
consisted of normalized protein supernatant, ¼ total volume loading dye made by diluting
1:9 2-Mercaptoethanol (Cat#1610710) and 4x Laemmli Sample Buffer (Bio Rad, Cat#
161047) loading dye and RIPA+PI to balance volume. Samples were resolved via SDSpolyacrylamide gel electrophoresis. Gel percentage and running voltage varied based on
the intended targets. Gels were transferred to methanol-activated 0.22μm or 0.45μm
pore size polyvinylidene difluoride (PVDF) membrane overnight (16-20hrs) at 25V. The
membrane was blocked for 1hr in 5% skim-milk (Criterion, Cat# C6961, Lot# 471903) or
2-5% BSA (Multicell, Cat# 800-095-EG, Lot# 800095043) diluted in 1x TBS to limit non-
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specific binding then probed with primary antibodies for BRCA2 (Proteintech, Cat# 197911-AP, 1:500), yH2AX (Cell Signalling, Cat# 9718S, 1:1000), p53 (Cell Signalling, Cat# 2524S),
GAPDH (Cell Signalling, Cat# D16H11, 1:1000), or β-Tubulin (Proteintech, Cat# 66240-1-Ig,
1:5000) in accordance with the manufacturer’s recommendations. Horseradish
peroxidase secondary antibody incubation was performed with anti-rabbit (Cell Signalling,
Cat# 7074, 1:3000 or Enzo, Cat# BML-SA204-0100, 1:5000) and anti-mouse (Enzo, Cat#
BML-SA204-0100) specificity.
Membranes were washed in 1xTBST (0.5% Tween20) and signal was generated by the
enhanced chemiluminescent (Bio-Rad, Clarity Western ECL) detection system. Images
were procured using the LICOR Odyssey FC imaging system and protein quantified by
densitometry using the associated analysis software (Image Studio v.5.2.5). Relative
abundance of target proteins was determined as the mean of target/loading control.
3.9 Endothelial Cell Isolation: Aortic segments were harvested and cleaned of
periadventitial adipose tissue via microdissection under stereoscopic microscope using
Vannas scissors and Dumont forceps. These segments were cut longitudinally and further
divided into 1-3mm x 1-3mm square pieces before they were immersed in 4°C endothelial
cell isolation buffer (ECIB [pH 7.4, 50mM NaCl, 80mM Sodium Glutamate, 6mM KCl, 2mM
MgCl2, 1mM CaCl2, 10mM Hemisodium HEPES, H2O, 0.2μm filtered and stored at 4°C,
10mM Glucose added on day of use]).
400μL of 4°C vascular smooth muscle cell isolation buffer (VSMCIB [pH 7.4, 55mM NaCl,
80mM Sodium Glutamate, 5mM KCl, 2mM MgCl2, 10mM Hemisodium HEPES, 0.1mM
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EGTA, H2O, 0.2μm filtered and stored at 4°C, 10mM Glucose added on day of use]) was
added to 1.5mL Eppendorf tubes. Tissues were added to the tubes and gently rocked to
resuspend. 50μL of Papain (Cedarlane-LS003119, 10μg/μL) and 50μL of DTT (Sigma-D9779,
10μg/μL) were added to each tube, flicked to resuspend tissues, and incubated at 37°C
for 30min, flicking every 10min.
290μL VSMCIB, 10ul CaCl2 (20mM), 100μL Collagenase IV (Cedarlane-LS004188, 10μg/μL),
and 100μL neutral protease (Cedarlane-LS02100, 10μg/μL) was added to each tube,
resuspended, and incubated at 37°C for 25min, flicking every 10min. Contents were mixed
by flicking and rocking for 1min and centrifuged at 120 RCF for 5min. 800μL supernatant
was removed and replaced by fresh ECIB and the pellet triturated with a 45° cut 1mL
pipette tip. Suspended endothelial cells were confirmed for viability under 10x
microscopy. Endothelial cells were pelleted and washed in 1x cold PBS prior to being lysed
in RIPA or Trizol for protein and RNA extraction respectively.
3.10 Immunohistochemistry: Mice tissues were fixed in situ – they were perfused with
10-20mL cold PBS followed with 4% paraformaldehyde (PFA) where applicable. Whole
tissues of the heart, aorta, lung, brain, kidney, liver, and spleen were stored in 4% PFA or
10% formalin for >48hrs. Prior to histological processing, these tissues were washed and
stored in 1x PBS. Tissues were embedded in paraffin wax and sectioned on a microtome
at 5um.
Gross histological examinations were performed on the heart, lung, liver, and aorta
stained with haematoxylin and eosin (H&E). Target proteins were revealed via standard
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immunohistochemical methods for horseradish peroxidase (HRP)-catalyzed 3,3’Diaminobenzidine (DAB) staining in conjunction with antibodies directed against BRCA2
(Proteintech, Cat# 19791-1-AP), yH2AX (Cell Signalling, Cat# 9718S), and Rad51 (Cell
Signalling, Cat# 8875S) in accordance with manufacturers guidelines for further tissue
section analysis.
TUNEL staining was performed on deparaffinized tissues sectioned at 5 microns and
counterstained with DAPI for nuclear identification. These images were captured at 60x
magnification and merged to illuminate endothelial apoptosis of the aorta and lung, while
the liver was used for positive control of apoptosis.
3.11 Myography: Functional myographic assays were performed on isolated aortic
arterial segments of BRCA2endo and BRCA2WT control male mice. Aortas were extracted
from mice euthanized by cervical dislocation and maintained in ice-cold Krebs buffer.
Aortas were cleaned of adipose and surrounding tissues aortic rings were mounted under
isometric tension on pins in myograph chambers (DMT620M; Danish Myograph
Technologies, Aarhus, DK). Vessel segments were equilibrated in Krebs buffer (pH 7.4,
37°C, continuously bubbled at 95 O2/5% CO2) with constitutes of 114 mM NaCl, 4.7 mM
KCl, 0.8 mM, KH2PO4, 1.2 mM MgCl2⋅6H2O, 2.5 mM CaCl2, 11mM D-glucose, and 20 mM

NaHCO3, 25mM HEPES.

Baseline contractile dose response to KCl (30, 60, 90 mM) was used for normalization
calculations and to determine tissue viability. Contractile response curve generation was
performed using phenylephrine (1-9-3-6 M) (PE). PE was used as a contractile agent prior
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to the generation vasorelaxation response curves induced by acetylcholine (Ach) (1-9-3-6
M), sodium nitroprusside (SNP) (1-9-3-6 M), and 2-furoyl-LIGRLO-NH2 (2FlI) (1-9-3-6 M),
each separated by a 20–40-minute washout period. Data were analyzed by testing for
linear correlation and statistical significance was determined by two-way ANOVA with
Bonferroni post-hoc test.
3.12 Echocardiography: Two-dimensional echocardiography (Visualsonics Vevo 2100
imaging system) was performed by a blinded investigator on sedated mice (4% induction,
1.5-2% maintenance isoflurane; body temperature maintained at 37-38°C). Their chests
were shaved, and residual fur was removed with Nair hair removal cream. B-Mode was
used to identify the area of interest and acquire 2-dimensional images of the heart while
short-axis M-Mode was utilized for a mono-dimensional, high temporal resolution images
of the mid-papillary muscle. Subsequent measurement of muscle relaxation and
actuation was done at three separate intervals each and averaged. Fractional shortening
was calculated as (LVEDD-LVESD)/LVEDD, and LV ejection fraction was determined by
((LVEDD^3-LVESD^3)/LVEDD^3) x 100.
3.13 Metabolic Caging: Metabolic measurements were performed via the
Comprehensive Lab Animal Monitoring System.(Guzman et al., 2013)(Janickova et al.,
2017) Metabolic chambers were maintained at room temperature (24 ± 1°C) wherein
BRCA2WT and BRCAendo mice were kept individually for 48 hours and provided water and
food (standard chow - powdered) ad libitum. Mice were allowed 24 hours of acclimation,
after which measurements for respiration (O2 intake and CO2 production), energy output
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at rest, food and water intake, and activity were measured at 10-minute intervals (OptoM3 Activity Monitor, Columbus Instruments) over a 24-hour period (12/12hr; light/dark).
3.14 Oil Red-O Staining of Aorta: Aorta Collection: Exsanguination was performed via
right ventricle cardiac puncture using a 27-gauge needle. 2-3 incisions were made in the
liver for drainage and perfusion was performed by left ventricle cardiac puncture using a
23-gauge syringe with 10mL of 1x cold PBS.
Tissues were collected as previously described with the exception of the heart, aortic arch,
thoracic aorta, and abdominal aorta which were extracted in contiguous segments and
cleaned of periadventitial adipose tissue via microdissection under stereoscopic
microscope using Vannas scissors and Dumont forceps. The aorta was transversely cut in
the atrial plane near the heart to separate the aorta including the aortic arch from the
heart containing the aortic root which was placed in 10% formalin for fixation and
histological analysis.
Plaque Staining: The aorta segment was placed in 10% formalin overnight up to 24hrs to
facilitate the removal of the remaining adventitia. These segments were washed 3 times
for 5min in 1mL of 78% methanol before staining for 50-60min in Oil Red-O solution (10mL
methanol, 4mL 1M NaOH, 0.028g Oil Red-O [Cat# O0625-25G, Lot# SHBM5455) powder.
Stained aortas were washed 2x in 1mL 78% methanol and placed in 1mL 4°C 1x PBS. The
following procedures were performed under cold PBS submersion aortas while avoiding
excessive manipulation to minimize plaque dislodgement and loss. Segments were
further cleaned of residual, stained adipose tissue. Aortic arch branches were trimmed,
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and the aorta was cut in the coronal plane along the outer curvature of the ascending
arch, hemisecting the remaining brachiocephalic, left common carotid, and left subclavian
arterial branches, then following along the descending thoracic aorta, cutting the full
length of the aorta. The aorta was pinned down on a black background using 10mm x
0.10mm minutien pins and exposed intimal surface was photographed at magnification
for en face plaque visualization.
The magnitude of plaque burden was calculated for the aortic arch using ImageJ (Fiji) via
manual segmentation (Figure 3-3) as percent plaque area (yellow dotted line) as a percent
of total vessel area (white dashed line) in a blinded fashion. Branches and plaque within
are not included in total vessel area or plaque calculations.

Figure 3-3. Aortic Arch Plaque Staining and Quantification. Representative en face image
of high-fat diet-fed mouse aorta exhibiting moderate to high plaque burden as stained by
Oil Red-O (magenta; encompassed by yellow dotted line) manually segmented and
calculated as a percent of total vessel area (white dashed line).
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Chapter 4. Results Part I
Baseline characterization of BRCA2endo mice

4.1 Generation of Endothelial Cell-specific BRCA2 knockout (BRCA2endo) Mice
To circumvent the embryonic lethality associated with systemic BRCA2 knockout mice,
the Cre-Lox P method was used to generate BRCA2endo mice as described in the methods
section (Figure 3-1, A). Initial crossing of stock mice was performed between homozygous
BRCA2 floxed and homozygous VE-Cre mice. Their progeny was heterozygous BRCA2
floxed and hemizygous for VE-Cre expression. These mice were back-crossed with
homozygous BRCA2 floxed mice to generate BRCA2fl/wt and BRCA2fl/wt;VE-CreTg/- mice. To
minimize the possibility of a Cre phenotype including Cre toxicity,(Silver & Livingston,
2001) and unintended DNA alterations/damage,(Loonstra et al., 2001)(Huh et al., 2010)
only mice hemizygous for Cre were used for experiments. Genotyping does not produce
results allowing for the resolution of one or two copies of VE-Cre, higher Cre recombinase
activity is toxic,(Company of Biologists, 2013) thus breeding of experimental mice was
performed between the crossing of BRCA2fl/wt and BRCA2fl/wt;VE-CreTg/- mice.
Experimental mice generated were BRCA2WT (BRCA2fl/fl;VE-Cre-/-, BRCA2fl/wt;VE-Cre-/-,
BRCA2wt/wt;VE-Cre-/-), BRCA2WT;Cre+ (BRCA2fl/fl;VE-CreTg/-), BRCA2het (BRCA2fl/wt;VE-CreTg/-)
and BRCA2endo (BRCA2fl/fl;VE-CreTg/-) mice. Where possible, BRCA2WT;Cre+ mice were
evaluated separately to ascertain the presence of a Cre phenotype. If not significantly
different than Cre- BRCA2WT mice, results were grouped.
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4.1.1 Genotyping
The genotype of each animal was determined via DNA extract and amplification for the
genes of interest. The results of which allowed for directed breeding pursuant to the
schematics in figure 3-1, A, and figure 3-2 and the selection of experimental and control
animals. The genotype of animals used for data generation was validated by tail DNA
extraction. BRCA2 flox status was determined primarily by testing for the presence of the
upstream loxP site (Figure 3-1, B) as resolved by primers B012/13 (Table 3-1), while
primers B014/15 (Table 3-1) were used to test for the presence of the downstream lox
site (Figure 3-1, B) as a redundant confirmation in a smaller subset of these animals.

A)

B)
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(C)

Figure 4-1. BRCA2 and VE-Cre Genotyping. Representative agarose gel images of
genotype variants as amplified by PCR for the (A) BRCA2 upstream lox site, (B) BRCA2
downstream lox site and (C) Vascular Endothelial Cre (VE-Cre).

4.1.2 Successful Deletion of BRCA2 at Transcript Level in the Endothelium of Endothelial
Cell-specific BRCA2 Knockout Mice
Isolated aortic endothelial cell or whole lung RNA was extracted, and cDNA was
synthesized. cDNA was used to ascertain BRCA2 deletion and the loss of BRCA2 transcript
using exon 11-specific primers. Results were visualized by PCR product run on agarose gel
electrophoresis. First, in isolated aortic endothelial cells, figure 4-2, A demonstrates PCR
product for BRCA2 after exon 11 deletion in BRCA2endo mice which is not visible in the
BRCA2WT mice as full length BRCA2 transcript is far longer and not able to be amplified
under these limited PCR conditions. Figure 4-2, B shows the overall transcript level in
whole lung tissue of BRCA2 exon 11 diminished in a genotype dependent manner and
figure 4-2, C demonstrates the same via quantitative polymerase chain reaction analysis
of BRCA2 exon 11.
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A)

B)

C)
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Figure 4-2. Confirmation of endothelial cell specific BRCA2 Deletion. (A) Agarose gel
image exhibiting the truncated BRCA2 (905 bp) PCR product produced by BRCA2 Exon 11
deletion only present in BRCA2endo mice. (B) PCR amplification of BRCA2 Exon 11 in wholelung RNA extract demonstrating the genotype-dependent reduction of exon 11 in
BRCA2endo and BRCA2het mice relative to their BRCA2WT counterparts. (C) qPCR results
from the amplification of BRCA2 Exon 11 and GAPDH in whole-lung RNA extract revealed
a significant difference between BRCA2WT (fold change = 1.5 ± 0.62, n=5), and BRCA2endo
(fold change = 0.4 ± 0.36, n=5) (p=0.0035), while BRCA2het (fold change = 1.0 ± 0.26, n=6)
was not significantly different from either. Data are presented as mean ± SD.

4.1.3 Loss of BRCA2 Protein in the Endothelium of Endothelial Cell-specific BRCA2
Knockout Mice
Immunoblotting of whole lung protein extract demonstrated a trend of decreased BRCA2
expression in BRCA2endo mice (Figure 4-3, A). Immunohistochemistry for BRCA2 presence
confirmed loss of BRCA2 protein in the endothelium of the lung and aorta of BRCA2endo
mice (Figure 4-3, B).
A)
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B)

Figure 4-3. (A) Immunoblot of protein extracted from whole-lung tissue lysate for BRCA2
with Beta-Tubulin as a loading control (n=2). (B) Histological images of BRCA2 antibodyincubated DAB-stained aorta and lung of BRCA2WT and BRCA2endo mice (5um, n=2).

4.2 Characterization of Endothelial Cell-specific BRCA2 Knockout Mice
Endothelial cell specific BRCA2 knockout mice were characterized at baseline (8-20
weeks) for mendelian ratio, weight, DNA damage, cardiac and vascular function, and for
metabolism.

4.2.1 Endothelial Cell-specific BRCA2 Knockout Mice are Born in Expected Mendelian
Ratio
Evaluating the Mendelian ratio of progeny born in transgenic crossing showed no
deviation from the expected ratio in males (Table 4-1), females (Table 4-2), or in total
progeny (Table 4-3).
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Table 4-1. Mendelian Ratio of Male Progeny

Table 4-2. Mendelian Ratio of Female Progeny

Table 4-3. Mendelian Ratio of Total Progeny

Mendelian Ratio: Endothelial cell specific BRCA2 heterozygous (BRCA2het) and
homozygous knockout male (Table 4-1, n=47), female (Table 4-2, n=23), and total (Table
4-3, n=70) mice are born in expected Mendelian Ratio. Chi-Squared analysis showed no
significant difference from the expected ratio.

4.2.2 Endothelial Cell-specific BRCA2 Knockout Mice Display Similar Weight at 8 Weeks
of Age
Weight was not found to be genotype-dependent at 8 weeks of age in males (Figure 4-4,
A) or females (Figure 4-4, B).
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A)

B)

Figure 4-4. Weight at 8 Weeks of Age. Data are presented as means ± SD. Weight at 8
weeks was not significantly different between (A) male BRCA2WT (n= 34, 22.4g ± 4.59),
BRCA2het (n= 20, 22.4g ± 3.87), and BRCA2endo (n=18, 24.3g ± 5.71) mice; or (B) female
BRCA2WT (n= 27, 17.4g ± 3.26), BRCA2het (n= 19, 17.8g ± 3.32), and BRCA2endo (n=14, 16.9g
± 2.82) mice.

4.2.3 Endothelial Cell-specific BRCA2 Knockout Mice Demonstrate No Signs of DNA
Damage and DNA Damage Repair in Endothelial Cells at Baseline
Aortas, lungs, and livers were collected from perfused mice. Tissues were fixed, cut, and
stained for γH2AX (Figure 4-5, A) and Rad51 (Figure 4-5, B). H2AX is phosphorylated to
γH2AX after the occurrence of DNA damage, while Rad51 is recruited by BRCA2 to the site
of DNA damage to initiate DNA damage repair. No difference was observed between
genotypes for γH2AX or Rad51 expression, indicating a similar extent of DNA damage and
repair between the groups.
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A)

B)
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Figure 4-5. Representative Histological Images. Aorta, lung, and liver were dissected
from perfused BRCA2endo, BRCA2het, and BRCA2WT littermates. Tissues were cut at 5
microns and sections were stained with antibodies for (A) yH2AX and (B) Rad51. Nuclei
are stained blue by hematoxylin and antibody signal is visible as brown precipitate formed
by horseradish peroxidase (HRP)-catalyzed Diaminobenzidine (DAB). Scale bar is 30um
(n=2/group).

4.2.4 Endothelial Cell-specific BRCA2 Knockout Mice Demonstrate No Signs of Apoptosis
in Endothelial Cells at Baseline
Sections of the aorta, lung, and liver were stained by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL), which detects DNA fragmentation generated
during apoptosis. These nuclei of the same tissue segments were counterstained by DAPI.
No TUNEL-positive cells were detected across genotypes in the aorta (Figure 4-6, A), and
virtually no TUNEL-positive cells were detected across genotypes in the lung (Figure 4-6,
B) or liver (Figure 4-6, C), with the only isolated incidence of TUNEL positivity in BRCA2WT
lung and BRCA2het liver shown as experimental validation.
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A)

B)
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C)

Figure 4-6. No Apoptosis in Endothelial Cells of BRCA2WT and BRCA2endo Mice.
Representative DAPI, terminal deoxynucleotidyl transferase dUTP Nick-End Labeling
(TUNEL), and colourized merged images of the (A) aorta and (B) lung show no apoptosis
in the endothelium of BRCA2WT, BRCA2het, or BRCA2endo mice. (C) Liver sections stained by
TUNEL were used as a positive control. n=2.

4.2.5 Endothelial Cell-specific BRCA2 Knockout Mice Display Similar Cardiac Function as
WT Mice at Baseline
Ultrasound was performed on male (Figure 4-8, A-B) and female (Figure 4-8, C-D) mice
and no significant genotype-dependent differences were found in left ventricle ejection
fraction or fractional shortening indicating similar cardiac function at baseline.
Echocardiographic images of B-mode showing the mouse chest cavity and heart in
transverse (Figure 4-7, A) and M-mode, which visualizes the diameter during oscillations
of the left ventricle used to determine LVEDD and LVESD (Figure 4-7, B).
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A)

B)

Figure 4-7. Echocardiographic Images and Measurements. Sample image of
echocardiograph in (A) B-mode delineating the cardiac region being probed by (B) Mmode displaying left ventricle end diastolic diameter (LVEDD) and left ventricle end
systolic diameter (LVESD).
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A)

C)

B)

D)

Figure 4-8. Similar Baseline Cardiac Function in Male and Female Mice at 8-16 Weeks of
Age. Echocardiography was performed on male and female mice. Data for male mice at
8-10 weeks and 14-16 weeks were not significantly different and these data sets are
combined to 8-16 weeks. No significant difference between genotypes was observed for
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(A) male left ventricle ejection fraction (LVEF) in BRCA2WT (n=11, 59.2% ± 12.64), BRCA2het
(n= 9, 60.5% ± 9.81), and BRCA2endo (n=9, 63.3% ± 7.67) or (B) left ventricle fractional
shortening (LVFS) in BRCA2WT (n=11, 26.2% ± 7.78), BRCA2het (n=9, 27.2% ± 6.17), and
BRCA2endo (n=9, 28.9% ± 5.51); or in in females for (C) LVEF in BRCA2WT (n=6, 63.3% ±
11.78), BRCA2het (n=5, 60.9% ± 14.83), and BRCA2endo (n=5, 57.7% ± 11.70) or (D) LVFS in
in BRCA2WT (n=6, 29.2% ± 8.22), BRCA2het (n=5, 28.0% ± 9.97), and BRCA2endo (n=5, 25.4%
± 6.78). Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc. Data
are presented as mean ± SD.
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4.2.6 Endothelial Cell-specific BRCA2 Knockout Mice Display Similar Vascular Function
as WT Mice at Baseline
Aortic segments were extracted, mounted on pins in Krebs buffer, and challenged with
increasing doses of the endothelial dependent vasodilators acetylcholine (Figure 4-9, AB) and 22-furoyl-LIGRLO-NH2 (Figure 4-9, C-D), and the endothelium independent
vasodilator sodium nitroprusside (Figure 4-9, E-F). Similar vasodilatory response to each
drug was observed across genotypes, indicating a lack of endothelial dysfunction in the
BRCA2endo mice.
A)

B)
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C)

D)
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E)

F)

Figure 4-9. Similar Vasoreactivity at Baseline in WT and EC-specific BRCA2 Knockout
Mice. Representative myographic tracings are shown for each vasodilator. Four
parameter sigmoidal dose response curve demonstrates similar dose-dependent
vasorelaxation response when vessels were subjected to (A-B) acetylcholine (ACh) (n=5,
p>0.05), (C-D) 2-furoyl-LIGRLO-NH2 (2FLY), or (E-F) sodium nitroprusside (SNP) BRCA2endo.
n=5, data are presented as mean ± SEM.
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Table 4-4

Table 4-4. Similar Vasoreactivity at Baseline in WT and EC specific BRCA2 Knockout Mice.
Vasoreactivity to acetylcholine (ACh), 2-furoyl-LIGRLO-NH2 (2FLY), and sodium
nitroprusside was not significantly different between BRCA2endo and BRCA2WT mice as
indicated by Emax and shared hill slope and -logEC50 best-fit values as calculated by the
generated four parameter sigmoidal dose response curve. n=5, data are analyzed by twoway ANOVA with Bonferroni’s post-hoc.

4.2.7 Endothelial Cell-specific BRCA2 knockout mice Display Similar Metabolic
Parameters as WT Mice at Baseline
Mice were placed in metabolic caging and monitored for respiration, activity, and food
and water intake. Similar metabolic function was observed between genotypes across all
metabolic parameters.
A)

B)
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I)
Figure 4-10. Similar Metabolic Function
at Baseline in BRCA2WT and BRCA2endo
mice. No significant difference was
observed during a 50/50 light/dark cycle
over 24 hours in (A) O2 consumption
between BRCA2WT (light=2567mL/kg/h ±
80; dark=3279 mL/kg/h ± 154) and
BRCA2endo (light=2435mL/kg/h ± 49;
dark=3205mL/kg/h ± 118) mice; or (B)
CO2
emission
between
BRCA2WT
(light=2332mL/kg/h ± 116; dark=3144 mL/kg/h ± 203) and BRCA2endo (light=2250mL/kg/h
± 57; dark=2867mL/kg/h ± 187); or (C) in respiratory exchange ratio between BRCA2WT
(light=0.91 ± 0.031; dark=0.96 ± 0.020) and BRCA2endo (light=0.92 ± 0.017; dark=0.89 ±
0.027); or (D) energy expenditure between BRCA2WT (light=0.35 ± 0.015; dark=0.46 ±
0.024) and BRCA2endo (light=0.36 ± 0.011; dark=0.47 ± 0.007); or (E) food consumption
between BRCA2WT (light=1.0g ± 0.31; dark=2.0g ± 0.28) and BRCA2endo (light=1.0g ± 0.12;
dark=1.4 ± 0.35); or (F) in water consumption between BRCA2WT (light=0.9mL ± 0.06;
dark=2.6mL ± 0.40) and BRCA2endo (light=1.2mL ± 0.13; dark=2.5 ± 0.67); or (G) total
activity between BRCA2WT (light=1819counts/h ± 99; dark=5357counts/h ± 1044) and
BRCA2endo (light=1524counts/h ± 239; dark=7051 ± 1243); or (H) ambulatory activity
between BRCA2WT (light=624counts/h ± 62; dark=2916counts/h ± 700) and BRCA2endo
(light=656counts/h ± 145; dark=4211counts/h ± 914); or (I) time asleep between BRCA2WT
(light=446min ± 21; dark=186min ± 31) and BRCA2endo (light=486min ± 13; dark=198min
± 36) mice. Data are presented as mean ± SEM, n=5.
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Chapter 4. Results Part II
HFD-exacerbated atherosclerosis in
atherosclerotic mouse (ApoE-/-) model

endothelial

cell-specific

BRCA2

deficient

4.3 Generation and Characterization of ApoE-/-;BRCA2endo – Atherosclerotic Mouse
Model Characterization
Breeding was executed pursuant to the schematic in Figure 3-2 to produce a cohort of
mice all lacking a functional ApoE protein (ApoE-/-) and of the same experimental
BRCA2;VE-Cre genotypes as described in section 4.1 (BRCA2wt/wt;VE-Cretg/-, BRCA2fl/fl;VECre-/-, BRCA2fl/wt;VE-Cre-/-, BRCA2wt/wt;VE-Cre-/-, BRCA2fl/wt;VE-Cretg/-, and BRCA2fl/fl;VECretg/-,). Again, where possible, BRCA2WT;Cre+ mice were evaluated separately and grouped
if results did not significantly differ from Cre- BRCA2WT mice.
4.3.1 Genotype Identification of ApoE Mutant Allele
Pro-atherosclerotic mice were generated by the addition of another transgene; an ApoE
mutation causing lipid dysregulation. The desired double mutation genotype was
identified to inform breeding. The possible permutations of the ApoE mutation are shown
below in Figure 4-11. The PCR product of 155bp represent WT and 245bp represents the
mutant ApoE allele.

Figure 4-11. ApoE Mutation Genotype. Representative agarose gel image of genotype
variants of ApoE mutation. Identification performed by ear tissue digest and amplified by
PCR using primers for the ApoE mutant allele (Table 3-1).
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4.3.2 ApoE-/-;BRCA2endo Mice are Born in Expected Mendelian Ratio
Evaluating the Mendelian ratio of progeny born in transgenic crossing aof ApoE-/- mice
showed no deviation from the expected ratio in males (Table 4-5), females (Table 4-6), or
in total progeny (Table 4-7).
Table 4-5

Table 4-6

Table 4-7

Tables 4-5 – 4.7. Mendelian Ratio for 2 ApoE-/-;BRCA2endo Mice: Male (Table 4-5, n=50),
female (Table 4-6, n=21), and total (Table 4-7, n=71) mice are born in expected Mendelian
Ratio. Chi-Squared analysis demonstrated no statistical deviation from expected ratio.
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4.3.3 ApoE-/-;BRCA2endo and Endothelial Cell-specific BRCA2 Knockout Mice Show Similar
Weight at 10 Weeks of Age
The weight of ApoE-/- mice at 10 weeks of age was not found to significantly differ based
on genotype in males (Figure 4-12, A) or females (Figure 4-12, B).

A)

B)

Figure 4-12 Weight at 10 Weeks of Age. Weight at 10 weeks was not significantly different
between (A) male ApoE-/-; BRCA2WT;Cre+ (n=4, 25.6g ± 5.30), ApoE-/-;BRCA2WT (n= 40, 26.9g
± 4.15), ApoE-/-;BRCA2het (n= 19, 27.2g ± 2.61), and ApoE-/-;BRCA2endo mice (n=29, 26.2g ±
3.27); or (B) female ApoE-/-;BRCA2WT (n= 30, 22.9g ± 4.04), ApoE-/-;BRCA2het (n= 13, 22.5g
± 2.39), and ApoE-/-;BRCA2endo (n=13, 22.7g ± 3.10) mice. Data are presented as mean ±
SD.

4.3.4 High-fat Diet Induced Weight-gain in ApoE-/-;BRCA2endo Mice
Weight at 10 weeks of age was similar between all tested genotypes. However, upon the
administration of high-fat diet, male and female ApoE-/-;BRCA2endo mice appear to be
undergoing accelerated net-weight gain up to 8 and 10 weeks HFD respectively, with male
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mice of this genotype losing weight after 8 weeks HFD. Moreover, when weight gain was
interpreted as a cumulative percent of body weight, this weight loss seems more drastic
and begins to emerge as early as 6 weeks in male ApoE-/-;BRCA2endo mice.

A)

B)

C)

D)
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Figure 4-13. Weight after 8 Weeks of High-fat Diet. Weight at 10 weeks was not
significantly different between (A) male ApoE-/-;BRCA2WT;Cre+ (n=4, 33.6g ± 4.75), ApoE/-;BRCA2WT (n=22, 35.9g ± 4.35), ApoE-/-;BRCA2het (n=15, 35.5g ± 4.52), and ApoE/-;BRCA2endo (n=9, 37.1g ± 5.45); or (B) female ApoE-/-;BRCA2WT (n=21, 31.9g ± 7.20), ApoE/-;BRCA2het (n=17, 29.3g ± 5.07), and ApoE-/-;BRCA2endo (n=7, 32.4g ± 5.27) mice. Mouse
weight after 12 weeks HFD was similar in (C) male ApoE-/-;BRCA2WT (n=12, 38.0g ± 5.44),
ApoE-/-;BRCA2het (n=7, 35.2g ± 5.07), and ApoE-/-;BRCA2endo (n=4, 35.3g ± 5.36); or (D)
female ApoE-/-;BRCA2WT (n=13, 28.8g ± 5.35), ApoE-/-;BRCA2het (n=9, 30.6g ± 4.52), and
ApoE-/-;BRCA2endo (n=4, 33.7g ± 5.88) mice. Data are presented as mean ± SD and analyzed
via one way ANOVA with Tukey’s post-hoc.
A)

B)

C)

D)
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Figure 4-14. Weight Gain on High-fat Diet. Graphs illustrating net weight from the
initiation of HFD and every two weeks in (A) males and (B) females as well as graphs
showing cumulative weight gain as a percentage of body weight from the initiation of HFD
and at every two-week interval in (C) males and (D) females. Data are presented as mean
± SEM.

4.3.5 High-fat Diet Induced Spleen Enlargement in ApoE-/-;BRCA2endo Mice
Mice were observed to have a high incidence of splenomegaly, with an overarching trend
towards increased spleen weights in the heterozygous and homozygous knockouts vs
wildtype control mouse spleen weight (Figure 4-15). Spleen-weight was significantly
higher in male 8-week-old homozygous (ApoE-/-;BRCA2endo) male spleens (Figure 4-15, A).
A)

B)
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C)

D)

Figure 4-15. Spleen Weight in HFD-fed ApoE-/mice. Significant difference was found in the spleen weight of (A) males fed HFD for 8
weeks between ApoE-/-;BRCA2WT (n=10, 0.141g ± 0.0271) and ApoE-/-;BRCA2endo (n=7,
0.216g ± 0.0848) (p=0.0227). While in this group, ApoE-/-;BRCA2het (n=6, 0.169g ± 0.0303)
was not significantly different than either. No significant difference was found in (B)
females fed HFD for 8 weeks between ApoE-/-;BRCA2WT (n=4, 0.179g ± 0.0506), ApoE/-;BRCA2het (n=6, 0.268g ± 0.0612), or ApoE-/-;BRCA2endo (n=3, 0.194g ± 0.0441) mice; or
(C) males fed HFD for 12 weeks between ApoE-/-;BRCA2WT (n=3, 0.0134g ± 0.0321), ApoE/-;BRCA2het (n=4, 0.217g ± 0.0494), or ApoE-/-;BRCA2endo (n=3, 0.262g ± 0.0823); or (D)
females fed HFD for 12 weeks between ApoE-/-;BRCA2WT (n=6, 0.179g ± 0.0260), ApoE/-;BRCA2het (n=3, 0.381g ± 0.1292), or ApoE-/-;BRCA2endo (n=4, 0.454g ± 0.4394). Data are
analyzed by one-way ANOVA with Tukey’s post hoc and are presented as mean ± SD.
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4.3.6 High-fat Diet Induced Significantly Higher Plaque Burden in the Aortic Arch of
ApoE-/-;BRCA2endo Mice
After feeding ApoE-/- mice a Western-type HFD for 8 and 12 weeks, a trend towards
increased atherosclerotic burden in the ApoE-/-;BRCA2het and ApoE-/-;BRCA2endo mice was
observed (Figure 4-16). Moreover, significant differences were found in males with 8week HFD-fed males exhibiting significantly higher aortic arch plaque as a percent of total
area in both ApoE-/-;BRCA2het and ApoE-/-;BRCA2endo genotypes vs ApoE-/-;BRCA2WT (Figure
4-17, A). Significantly higher plaque percent was also observed in the aortic arch of ApoE/-;BRCA2endo vs ApoE-/-;BRCA2WT in 12-week HFD-fed male ApoE-/- mice (Figure 4-17, B).
A)

B)
Figure 4-16. Aortic Plaque Burden of
Mice
Fed
High-Fat
Diet.
Representative images of (A) Oil RedO-stained aortas of 12-week HFD-fed
male mice and (B) en face imaged
aortas of male mice fed a high fat diet
for 8 weeks demonstrating increased
atherosclerotic plaque burden in the
aortic arch of heterozygote and
homozygote endothelial cell-specific
BRCA2 knockout mice on an ApoE
null background.
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A)

C)

B)

D)
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Figure 4-17. Aortic Arch Plaque Burden as a Percent of Total Area. Significant difference
in aortic arch plaque burden was found in (A) males fed HFD for 8 weeks between ApoE/-;BRCA2WT (n=10, 3.4% ± 1.28) and ApoE-/-;BRCA2het (n=6, 6.6% ± 2.25) and ApoE/-;BRCA2endo (n=6, 6.9% ± 3.60) mice (p=0.0135). No significant difference was found in
the aortic arch in (B) females fed HFD for 8 weeks between ApoE-/-;BRCA2WT (n=5, 3.0% ±
1.90), ApoE-/-;BRCA2het (n=6, 5.3% ± 3.68), or ApoE-/-;BRCA2endo (n=3, 6.2% ± 5.29) mice.
Aortic plaque percent total area in (C) males fed HFD for 12 weeks was significantly
different between ApoE-/-;BRCA2WT (n=8, 11.29% ± 4.49) and ApoE-/-;BRCA2endo (n=5,
20.5% ± 6.16) (p=0.0091) mice, but ApoE-/-;BRCA2het (n=7, 15.9% ± 3.33) was not
significantly different from either. (D) Females fed HFD for 12 weeks did not differ
between ApoE-/-;BRCA2WT (n=6, 11.0% ± 3.03), ApoE-/-;BRCA2het (n=6, 15.6% ± 6.20), or
ApoE-/-;BRCA2endo (n=3, 17.4% ± 2.28). Data are analyzed by one-way ANOVA with Tukey’s
post hoc and are presented as mean ± SD.
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Chapter 5. Discussion
5.1 Discussion Introduction
The nascent field of cardio-oncology has been established in light of an appreciation for
the ever-growing understanding of existing overlaps and interactions between
cardiovascular diseases and cancer. Links between breast cancer and atherosclerosis are
well established,(Mai et al., 2009)(Anna Öfverholm, Zakaria Einbeigi, Antonia Wigermo,
2019)(Kat et al., 2017)(Sajjad et al., 2017)(Geoffrey et al., 2017)(Miao et al.,
2017)(Asselbergs et al., 2012) however, there is currently a need for a greater level of
scrutiny into genetic and molecular pathophysiological factors shared by these diseases.
BRCA1 and BRCA2 mutations disproportionately affect women and predispose them to a
high risk of breast and ovarian cancer.(Rebbeck et al., 2015)(Thompson & Easton,
2002)(Roy et al., 2012) In these patients, cardiovascular disease is a common comorbidity
and is present at rates higher than that of the general population; partly due to cancer
treatment-induced CVD.(Kat et al., 2017)(Fairweather, 2014)(Anna Öfverholm, Zakaria
Einbeigi, Antonia Wigermo, 2019) Yet even when controlling for common associated
cancers, BRCA mutation carriers also present with an earlier mortality when compared to
non-carriers(Mai et al., 2009) – but the precise reason for these excess deaths is unknown.
BRCA mutations hinder DNA damage repair allowing for accumulated DNA damage
leading to cancer, cellular dysfunction, or apoptosis. Endothelial injury and dysfunction
are also early presentations of the inflammatory disease, atherosclerosis.(Suzuki et al.,
2013)(M. Li et al., 2018) Endothelial dysfunction emerges as a result of DNA damage,
oxidative stress, and apoptosis;(Ballinger et al., 2002)(Lord & Bobryshev, 2002)(Marrocco
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et al., 2017)(Suzuki et al., 2013) all of which are also contributors to
carcinogenesis.(Negrini et al., 2010)(Heemst et al., 2007) Progression of atherosclerosis
in turn promotes increased rates of endothelial cell DNA damage(Botto et al., 2001)(Shah
et al., 2018)(S. Singh et al., 2020)(Gray et al., 2015)(Botto et al., 2001)(E. P. K. Yu & Bennett,
2014)(Andreassi, 2008) and BRCA1&2 are crucial factors in cellular homeostasis(Zhao et
al., 2017)(Rocca et al., 2015)(Deng, 2006) and the virtually error-free repair of double
stranded breaks mechanized by homologous recombination repair.(Rocca et al.,
2015)(Roy et al., 2012) Unification of these factors coalesces into a rationale for a
comprehensive evaluation of endothelial BRCA1 and BRCA2 in loss-of-function models of
atherosclerosis.
Previous work by our group has demonstrated a protective role played by BRCA2 when
cells are exposed to oxidative stress induced by oxidized low-density lipoproteins.(S. Singh
et al., 2020) This fundamental study revealed an urgent need for further assessment of
the role of endothelial BRCA2 in atherosclerosis. Human germline mutations in BRCA2 are
systemic and generally result in haploinsufficiency due to mutated copy inheritance
leaving only one non-mutant copy which is inadequate for normal function. Impaired
function of a single BRCA allele may also result in the second copy being
compromised(Salmena & Narod, 2012) and the loss of heterozygosity (LOH) as can be
seen in many tumors that exhibit LOH.(Sedic et al., 2015) Emulating a systemic
knockout/knockdown of BRCA2 in mice is challenging as the gene is developmentally
critical and systemic ablation of BRCA2’s exon 10/11 causing embryonic lethality prior to
day 9.5 of development with these mice demonstrating increased p21 expression and

84

hindered proliferation – demonstrating a critical role of BRCA2 in embryogenic cellular
proliferation.(Hakem et al., 1996) Exon 11 is the largest segment of BRCA2 and shares
58% protein homology between mouse and humans and contains the Rad51-interacting
BRC repeats that are highly conserved.(Bignell et al., 1997) Thus, a BRCA2 Exon 11
knockout is translationally relevant, but embryonically lethal. To bypass this limitation
and demonstrate the effect of loss of endothelial BRCA2 on atherosclerosis, we developed
two novel mouse strains utilizing the Cre-LoxP system to selectively expunge BRCA2 from
only the endothelium. The first is a single knockout of endothelial BRCA2 and the second
compounds this strain on an ApoE mutation background, creating a relevant in vivo model
of atherosclerosis.
Our team has extensive experience with successful tissue specific Cre-mediated BRCA
knockouts in mice and previous work has shown these models to exhibit no baseline
phenotype,(K. K. Singh et al., 2009)(K. K. Singh et al., 2012)(Shukla et al., 2011) yet, under
stress conditions, a protective role emerged for BRCA1 as a limiter of inflammation(Teoh
et al., 2013) and oxidative stress;(Chessex et al., 2013)(Lovren et al., 2014) and a
safeguard against atherogenesis(K. K. Singh et al., 2009). Moreover, both BRCA1 and
BRCA2 are evidenced to defend against cardiac dysfunction.(Shukla et al., 2011)(K. K.
Singh et al., 2012) Given the developmental challenges posed to an organism lacking
BRCA2 in a systemically significant cell type such as the endothelium, the BRCA2endo
mouse was evaluated against wildtype and heterozygote knockout littermates for
baseline phenotyping congruent with previous Cre-LoxP knockout models, including gross
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observations, metabolic analysis, and cardiac and vascular assessment as relevant
functional metrics of cardiovascular dysfunction.
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5.2 Discussion of Results Part I
Identification and genotyping of each animal were performed via ear clipping and tissue
DNA extraction. Further, in a subset of these animals, endothelial BRCA2 loss was
substantiated. Whole lung tissue extract was used to confirm the knockout status of
animals at the transcriptional/RNA and translational/protein levels given the tissue
composition of approximately 30-40% endothelial cells. Under PCR parameters limiting
the amplification size to ~1000-1200 bp by reducing the amplification time to 1 min given
the expected nucleotide addition rate by Taq Polymerase in PCR being ~20 nucleotide/sec,
primers spanning BRCA2’s exon10 through exon14 produced the shortened RNA product
in BRCA2endo mice after the removal of the gene’s extensive exon 11 via Cre-loxPmediated deletion. While the presence of this truncated mRNA product indicated
transcription, the product is likely unstable, transient, and subject to degradation.
Furthermore, the removal of the BRC repeat-containing exon 11 would render
recruitment of Rad51 by BRCA2 and ensuing DNA damage repair impossible should the
protein be synthesized. However, we did not observe a shortened protein in our knockout
mice as previously reported in cardiomyocyte specific BRCA2 knockout mice.(K. K. Singh
et al., 2012) This deletion was further validated via PCR amplification and agarose
electrophoresis visualization using exon 11 specific primers which revealed the expected
considerable reduction of the presence of this exon in both BRCA2het and BRCA2endo mice.
Lastly, exon11 F/R primers were again used to corroborate these results with qPCR
amplification and fold change analysis revealing a genotype-dependent significant
reduction of BRCA2 transcript in BRCA2endo mice.
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Final confirmation of BRCA2 knockout was performed via immunoblotting and
immunohistochemistry for the BRCA2 protein . This is critical as cells lacking the BRCA2
protein are unable to effectuate an efficient DNA damage repair response and the
existence, or lack thereof, of functional endothelial BRCA2 protein is the lynchpin of the
study. Whole lung tissue protein extract and immunoblot for BRCA2 and β-Tubulin
demonstrated a genotype-associated reduction in the amount of BRCA2 protein. These
results were further substantiated with immunohistochemistry for BRCA2 in both aortic
and lung tissues wherein the endothelial layer is clearly visible and shows extensive
positivity for BRCA2 in BRCA2WT mice while being greatly reduced in BRCA2het and
BRCA2endo mice.
Studies of young single knockout mice include the analysis of metrics used to reveal the
existence of any aberrant or adverse endothelial cell phenotype in the knockout as
compared to its WT control littermates. The data generated herein are critical for
comparison and interpretation of results of further studies utilizing this novel strain;
including that of any accelerated or increased atherosclerotic burden in ApoE-/-;BRCA2het
and ApoE-/-;BRCA2endo mice.
Evaluating the Mendelian ratio of litters born as a result of crossing these two transgenic
strains is an early and necessary step that serves to identify embryonic lethality. Since
systemic knockout of BRCA2 is known to carry this complication due to early
developmental necessity, the expected mendelian ratio observed in males and females,
as well as when sexes are aggregated, indicated a lack of developmental perturbance due
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to BRCA2 loss in the endothelium. VE-Cadherin only becomes detectable at trace levels
of activity at day 7.5 of embryonic development(Giannotta et al., 2013) and by this point,
the mouse embryo has progressed significantly into embryogenesis and reached late
gastrulation(Kojima et al., 2014) – indicating litter viability was not impacted by loss of
endothelial BRCA2 excised by Cre expressed under the control of the VE-Cadherin
promoter. Moreover, no discernable difference in weight was observed between
genotypes in males or females at 8 weeks of age or at any other timepoint measured.
DNA damage is a physiological event that requires repair for immediate cellular
homeostasis as well as long term organismal survival. Without BRCA2 functioning in the
endothelium, we expected an accumulation of DNA damage in these cells. As discussed,
the phosphorylated modification of H2AX to γH2AX is an early sensor and initiator of the
homologous recombination repair pathway of double stranded breaks. Therefore, an
increased presence of γH2AX indicates an excess of double stranded breaks. Within the
HRR pathway, Rad51 functions in conjunction with BRCA2 to effectuate the localized
repair of these breaks in the DNA via foci formation. Both molecules may be used as
proxies for DNA damage and repair. Representative images of the aorta, lung, and liver
were chosen to visually evaluate the effect of DNA damage in mice with endothelial cell
specific deletion of BRCA2. The aorta and lung were chosen for endothelial layer
identification and the liver as a DNA damage positive control. Immunohistochemical DAB
staining for each of these molecules demonstrate no observable genotype-driven effect
of DNA damage or response in BRCA2het or BRCA2endo mice compared to their WT control
littermates – a result that may be due to a low rate of DNA damage in these mice given
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their low stress hermetic environment and their young age. These findings suggest that
the setting and time point are insufficient to allow for DNA damage accumulation to
emerge at 26 weeks of age. This finding is in line with other data generated by our group
in endothelial- or cardiomyocyte-specific BRCA1 or BRCA2 knockout mice respectively
wherein DNA damage was not observed to be increased at baseline.(K. K. Singh et al.,
2009)(K. K. Singh et al., 2012)
Increased rates of apoptosis are a predictable consequence of accumulated DNA damage
which may overwhelm a cells ability to mitigate it through repair mechanisms such as via
BRCA2’s integration in the homologous repair pathway. Apoptosis was detected by TUNEL
staining of histological sections and with this method we examined sections of the aorta
and lung to determine the rate of apoptosis in the endothelium of WT, BRCA2het and
BRCA2endo mice, and in liver sections used for each of these genotypes as a positive control.
At 26 weeks of age, these mice did not exhibit any signs of endothelial apoptosis in any
group which is consistent with the lack of DNA damage and repair observed via γH2AX
and Rad51 staining in mice of this age group.
Left ventricle ejection fraction (LVEF) represents a percent of the total amount of blood
squeezed from the heart and is an indication of heart health and assessing the risk of
coronary artery disease,(Qian-qian Guo et al., 2020) compromised LVEF can be caused by
cardiomyopathy,(Agstam et al., 2020)(Zou et al., 2014) previous heart attack causing
muscle damage,(Zeb et al., 2013) mitral-valve malfunction,(Grayburn & Smith, 2014) and
chronic hypertension.(Little, 2008) Left ventricle fractional shortening (LVFS) may be used
as a potential predictor for coronary artery disease outcomes in some individuals.(Qian-
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qian Guo et al., 2020) Heart function may be affected by endothelial function via altered
cardiac remodelling and misfiring of paracrine signalling by endothelial cells to
cardiomyocytes and impairing their contractile function(Noireaud & Andriantsitohaina,
2014)(Segers et al., 2018) and demonstrating the value of assessing cardiac function of
BRCA2endo knockout mice. Cardiac health of the BRCA2 endothelial knockouts alongside
wildtype littermates was evaluated via ultrasound measurements for LVEF and LVFS
(Section 3.12). Male mice between 8 and 16 weeks of age showed a slight trend towards
increased LVEF and LVFS in heterozygous and homozygous BRCA2 knockouts vs wildtype.
In females of 16-18 weeks of age, a trend emerged in the opposite direction for both LVEF
and LVFS. As neither demonstrated significant differences, it is likely that we are observing
variation in otherwise healthy individual mice. However, these trends are worth further
exploring by repeating this experiment in older male and female mice as well as assessing
DNA damage and repair, apoptosis, ischemia, and hypoxia in the hearts of these animals.
Myography performed on aortic segments was used to assess vascular function at 8-10
weeks of age. Acetylcholine (ACh) was used to stimulate an endothelial-dependent
vasodilation response by triggering endothelial synthesis of nitric oxide. Similarly, 2furoyl-LIGRLO-NH2 (2FLY) causes vasorelaxation via activity as a proteinase-activated
receptor 2 (PAR2) agonist resulting in an increase in intracellular calcium and the
synthesis of nitric oxide. Lastly, sodium nitroprusside (SNP) tests the vasorelaxation
response independent of endothelial function by directly breaking down into nitric oxide
to stimulate the relaxation of vascular smooth muscle cells. No discernable difference was
observed in the dose response curves generated by increasing amounts of the vasoactive

91

drugs ACh, 2FLY, or SNP. Furthermore, analysis of logEC50, Emax, and hill slope of the curves
generated by four parameter sigmoidal dose response curve for each agonist revealed no
significant difference between the aortic response of BRCA2endo and WT mice (Table 4-4).
Vasorelaxation response between genotypes did not differ with respect to endotheliumdependency when challenged by these three chemicals, thus, it was determined under
these parameters that vascular function was maintained in a genotype-dependent
fashion at baseline.
Metabolic cages provide quantification data of respiration, activity, and food and water
intake. Similar metabolic function was observed between genotypes across all metabolic
parameters. BRCA2endo and BRCA2WT mice were monitored for these criteria and no
significant difference was found in respiration, energy expenditure, food or water intake,
activity, or time asleep, demonstrating a lack of metabolic abnormalities in young mice
due to endothelial loss of BRCA2.
The aggregation of these data demonstrated that endothelial BRCA2 is dispensable for
cardiovascular function at baseline and represents the essential foundation for
comparison in determining the effect of loss of endothelial BRCA2 under stress conditions
such as atherosclerosis.
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5.3 Discussion of Results Part II
There are clear benefits to using mouse models of disease as a translational bridge
between cell and human studies. However, there are some limitations in their use as an
atherosclerotic model.(von Scheidt et al., 2017) Mice don’t naturally develop
atherosclerosis due to bile composition and reverse cholesterol transport differences
compared to humans that results in an anti-atherogenic lipid profile that needs to be
overcome.(Oppi et al., 2019) Given these limitations, rather than feeding the BRCA2endo
mice a HFD, induction of atherosclerosis was facilitated by integrating an ApoE mutation
transgene on the EC-specific BRCA2 knockout mice. ApoE mutant mice are well described
for their propensity towards atherosclerotic development due to reduced hepatic and
intestinal uptake of ApoB-containing lipoproteins including VLDL and LDL – and the
consequently increased cholesterol-containing molecules circulating within the blood
stream resulting in hypercholesterolemia.(Bruffearts et al., 2017)(Ishibashi et al., 1994)(S.
H. Zhang et al., 1992) Studies using ApoE-/- mice are extensive and atherosclerosis under
various experimental conditions has shown ApoE-/- mice demonstrate modifications to
the inflammatory response,(Xue-Mei et al., 2017)(Han et al., 2017)(Di Bartolo et al., 2011),
heavy metal exposure,(Oliveira et al., 2019) comorbidities such as diabetes(Han et al.,
2017)(Di Bartolo et al., 2011) or cancer,(Tanaka et al., 2016) irradiation,(Mitchel et al.,
2011)(Gabriels et al., 2014) the composition of the gut microbiota,(Zhu et al., 2018)(F.
Wang et al., 2020) alterations in lipid regulation/metabolism,(Di Bartolo et al.,
2011)(Mahmood Hussain & Goldberg, 2018)(Gui et al., 2016) and by changes in reverse
cholesterol transport.(Y. Xu et al., 2014) Therefore, creating an atherosclerotic mouse
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model in our studies involved implementing an additional ApoE transgene mutation on
the BRCA2endo background.
ApoE-/- mice are known to exhibit monocyte-endothelial attachment after 6-8 weeks and
develop atherosclerotic lesions similar to human atherosclerosis within 8-10 weeks on a
standard chow diet.(Meyrelles et al., 2011) However, as the effects of DNA damage are
magnified under increased cellular stress, we selected a controlled mouse diet which
performs as an analog for the human Western-type diet (Section 3.1). This diet is
established as used in conjunction with ApoE-/- strains and is reported accelerate
atherogenesis such that these mice exhibit an early increase in cholesterol,(S. H. Zhang et
al., 1992)(Nakashima et al., 1994) lesions and foam cells at 6-10 weeks,(Nakashima et al.,
1994)(Nakashima et al., 1998) and fibrous plaque and subsequent cap formation at 15
and 20 weeks respectively.(Nakashima et al., 1994) This diet was chosen not only as a
Western diet mimic, but also as it contains relatively low cholesterol (0.2%) as compared
against many atherogenic diets (1.25%).(Hedrick et al., 2000)(Oppi et al., 2019) This
ideally mitigates any extreme lesion formation and limits plaque saturation allowing for
the identification of more subtle differences in plaque formation and lesion development.
Initial crossbreeding of BRCA2endo mice with ApoE-/- mice produced ApoE-/-;BRCA2het mice,
with 50% of individuals expressing VE-Cre. Further crossing these mice bred out any nonmutant ApoE genes and established the atherosclerotic (ApoE-/-), BRCA2 endothelial
knockout mouse line.
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As with the single endothelial cell-specific BRCA2 knockout mice, ApoE-/-;BRCA2 mice
were born in expected Mendelian ratio. The increased background/transgenic or
functional stress as a result of ApoE mutation introduction does not appear negatively
impact embryonic survival. However, of note is the relatively low female to male ratio of
pups born of 0.42 vs the expected equal birth rates of male and female mice. Supporting
this skewed ratio is research showing higher rates of males born to mothers fed high-fat
diet compared to standard chow or low-fat diet-fed mice.(Rosenfeld et al., 2003) Lipid
dysregulation and early hypercholesterolemia in ApoE-/- mice may induce a compounding
physiological effect and explain the altered ratio in these mice, but it does not preclude
the possibility of an inbreeding/background effect or early developmental issues.
Weight at 10 weeks of age was measured at the initiation of HFD. At this point, weight did
not differ between the BRCA2 genotypes of ApoE-/- mice for either males or females and
were of overall healthy in appearance and of average weight. The weight of these mice
was also measured at every 2-week interval post HFD initiation. At the relevant timepoints
of 8 and 12 weeks for aortic/tissue extraction and plaque quantification, weight did not
appear significantly different between genotypes or in either sex. Somewhat more
interesting is the weight gain of these mice as illustrated by net weight at each measured
interval and as cumulative percent body weight change. Net weight of ApoE-/-;BRCA2endo
mice is consistently higher in females and males with the exception of males at 12 weeks.
A decline in net weight and weight gain of ApoE-/-;BRCA2endo males appears to begin after
10 weeks of HFD. These data are consistent with previous studies on mouse weight gain
under standard chow and high-fat diet wherein mouse weight tends to plateau and
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percent weight gain drops over time.(N. S. Jones et al., 2019)(Timon et al., 1970)(Timon
& Eisen, 1969)
Upon examination, ApoE-/- mice on HFD exhibited notable splenomegaly. The decision
was made to weigh the organ given the obvious phenotype. Spleen enlargement and
weight gain is a an established genotype driven effect in ApoE-/- mice.(Y. Wang et al.,
2012) Enlarged spleens are primarily asymptomatic and may result from various
underlying conditions. Metabolic disorders such as Gaucher or Neimann-Pick disease
which hinders lipid metabolism breakdown may cause spleen and liver fat retention
causing enlargement.(Razek et al., 2019)(Parra et al., 2011) The spleen is partly
responsible for regulating the immune response to systemic inflammation as seen in
atherosclerosis. Inflammation exacerbated by an unhealthy diet and in turn associated
with spleen enlargement.(Barrea et al., 2018) Under the stress of obesity, there exists a
connected axis of endothelial dysfunction and inflammation of the heart and
spleen(Tourki et al., 2020) and endothelial dysfunction has also been shown to play a
direct role in promoting splenomegaly.(Jiang et al., 2015) While a more rare cause of
enlargement, splenic infarction occurs when the spleen’s blood flow is interrupted and
may be induced by atherosclerotic clots and is another mechanism by which spleen
enlargement manifests.(Frippiat et al., 1996)(Gascon et al., 1999)
Interestingly, upon weight analysis, there was a significantly higher spleen weight in 8week HFD-fed male ApoE-/-;BRCA2endo mice and an otherwise observable trend towards
the lowest spleen weights being in ApoE-/-;BRCA2WT for each sex and at both 8 and 12
weeks HFD. In all cases except for 8-week HFD-fed female where ApoE-/-;BRCA2het spleen
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weight was the highest – increased spleen weight trended in BRCA2 heterozygote then
homozygote endothelial knockout, ApoE-/- mice.
While generally not considered a direct corollary to atherosclerotic magnitude, the
genotype dependency of increasingly larger spleens in the knockout mice provide
promising avenues for further work. Given the discussed links between spleen weight and
such factors as diet, lipid metabolic regulation, endothelial dysfunction, inflammation,
and atherosclerosis, as well as the existence of a known cardiac-spleen-liver axis, there is
compelling reason to further investigate the precise reasons for the observed splenic
phenotypes. A possible culprit of the observed splenomegaly is lipid retention, which is of
primary interest due to evidence for BRCA2’s role in lipid regulation,(Genetic et al.,
2015)(Oliverio et al., 2020) yet further quantitative histological and molecular analysis of
these tissues is required and underway to reveal any underlying mechanisms.
The primary goal of this study is to evaluate the extent of atherosclerosis of ApoE/-;Brca2endo mice

after high-fat diet. Atherosclerosis occurs primarily in branched regions

and areas of that vasculature that experience turbulence or low shear stress.(Foteinos et
al., 2008)(Tricot et al., 2000) The aortic arch encompasses each of these factors and is
routinely used as a standard for atherosclerotic measurements and the selected ApoE-/strain consistently develops plaque in this location due to its susceptibility. Endothelial
injury and plaque accumulation occurs preferentially here, and the arch and thoracic
aorta may be used to evaluate atherosclerotic burden.
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Evaluation of the aortic arch plaque as a percentage of total area revealed that at 8 weeks
of HFD, male mice exhibited a significantly increasing area of plaque in ApoE-/-;Brca2het
and ApoE-/-;Brca2endo, and after 12 weeks HFD, male mice exhibited significantly higher
aortic arch plaque burden in ApoE-/-;Brca2endo mice vs ApoE-/-;BRCA2WT. These results are
distinctly visible in representative whole stained, and en face minutien pin mounted
aortas. Moreover, in females after 8 and 12 weeks HFD, a compelling trend in the same
direction is emergent. It is possible that the significant difference is only visible in males
at 8 and 12 weeks due to an early onset of plaque formation in male mice given their
relatively higher vulnerability to CVD (ischemic heart disease in particular) compared to
their female counterparts.(Kaplan et al., 1996) Men have a statistically earlier onset
across all manifestations of CVD and tend towards coronary artery disease while women
are at a higher risk of cerebrovascular disease and heart failure.(Leening et al., 2014)
These differences are thought to be due to differential expression of endogenous
hormones between the sexes(Rexrode, 2017) and while menopause appears to
exacerbate atherogenesis as communicated,(Kat et al., 2017)(Fairweather, 2014) the
result a later onset of severe cardiovascular disease. Moreover, in the stained aortas of
BRCA2WT/het/endo;ApoE-/- mice, the great majority of branches along the descending
thoracic aorta to the iliac branch were heavily burdened by plaque past the 12-week mark
with notably high burden at 8 weeks – suggesting peripheral artery disease.
This evidence presents a strong correlation between greater atherosclerotic burden and
loss of endothelial BRCA2. Should the results of this study be proven to translate to human
studies, there may be a paradigm shift specifically in how both males with BRCA2
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mutation are screened and evaluated, but also in females receiving BRCA-related cancer
treatments which, as previously iterated, contain their own cardiovascular risks including
cardiotoxicity(Schmidt et al., 2016)(Aleman et al., 2007)(Belt-dusebout et al., 2021) and
metabolic syndrome.(Dørum et al., 2008) These patients and those with CVD risk factors
may also stand to benefit from BRCA2 targeted gene therapy, providing the impetus for
development of novel treatments and opening the door for future studies into the roles
and effects of BRCA2.
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Chapter 6. Conclusions and Future Directions
6.1 Conclusions
Extensive phenotyping of the single knockout mouse revealed endothelial BRCA2 as being
dispensable at baseline (8-16 weeks of age). This is congruent with how impaired DNA
damage repair results in a progressive accumulation of DNA damage over time. At a young
age, these effects may not produce any clinically relevant differences. However, with time
or stress, accumulation may overwhelm the capacity to mitigate the deleterious effects
of chronic unrepaired DNA and result in the emergence or exacerbation of pathologies
such as cancer or cardiovascular disease. In this study, the single BRCA2 knockouts at a
young age were under no acute stress and were not phenotypically different than their
control littermates.
Creating a double knockout with endothelial BRCA2 and ApoE functional loss and inducing
atherosclerosis on a high-fat diet provided the parameters for the evaluation of these
mice under atherogenic-stress conditions. After 8 weeks of HFD, male heterozygote and
homozygote endothelial

BRCA2

knockout mice

showed

significantly greater

atherosclerotic burden in their aortic arches as compared to ApoE-/-;BRCA2WT controls and
significantly more plaque was also observed in 12-week HFD-fed ApoE-/-;BRCA2endo male
mice. Females after 8 and 12 weeks HFD also demonstrated a compelling trend towards
an increased atherosclerotic magnitude in heterozygote and homozygote knockout mice.
The addition of more mice to these groups as well as additional intervals of HFD are
ongoing and may serve as statistical reinforcement to delineate genotype-dependent
atherogenesis.
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With the knowledge gained in this study, we have identified BRCA2 as an integral
protector against atherosclerosis and a novel therapeutic target for overexpression in ECs
by adenoviral or lentiviral vectors carrying the BRCA2 gene as controlled by EC-specific
promoters or by stimulating BRCA2 endothelial expression in atherosclerotic patients.
Further, we believe this work provides justification for the consideration of expanded
screening for the early onset of cardiovascular-related complications in BRCA2 mutation
carriers.
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6.2 Study Limitations
Our primary limitation is the number of mice at each HFD interval for certain genotypes.
Where a strong trend exists, further mice should be added to determine the veracity of
these trends.
Our model only lacks BRCA2 in the endothelium. While excellent for understanding the
role of endothelial BRCA2, atherosclerosis is a disease of the complete vasculature and
involves extensive participation and remodelling by vascular smooth muscle cells,
amongst

other

complex

cellular

interactions.

As

this

is

not

a

systemic

knockout/knockdown, the effect of BRCA2 loss in other participating cell types is not
being addressed and cannot be evaluated within the scope of our model. Moreover, as
frequently whole lung tissue was used in experiments, isolating lung endothelial cells for
validation of these results would be prudent. Moreover, as isolation of aortic endothelial
cells may have resulted in VSMC contamination given the followed protocol, flow sorting
will be used for definitive isolation.
Molecular work is currently lacking in the atherosclerotic model and experiments for
immunohistochemistry, qPCR, and immunoblotting for established for markers of DNA
damage and repair, apoptosis, and proliferation are underway.
Cardiovascular functional data may also be generated in atherosclerotic mice to evaluate
the relative effect on the double knockout on HFD vs baseline.
Our earliest timeframe is at 8 weeks HFD and the data indicates that these mice already
exhibit a potentially earlier initiation of atherosclerosis. The addition of a 4-week HFD
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cohort would allow for the identification of the onset of atherosclerotic plaque and
possibly delineate differences in plaque emergence between genotypes.
Finally, the limitations of COVID including delayed collaborative efforts as well as
deliveries of lab supplies and difficulties in scheduling and obtaining access to necessary
equipment/machines for experiments. Thus, said delays resulted in a wider age range
than desired in our baseline mouse studies (BRCA2endo phenotyping).
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6.3 Future directions
We have demonstrated that atherosclerosis is exacerbated in mice oh a high-fat,
Western-type diet. With this knowledge, it is imperative that follow-up studies on human
samples of BRCA2 mutation carriers be performed to identify any translation into human
patients.
As cardiovascular diseases are age-associated, further studies on aged mice of the single
knockout genotype are ongoing and may include the non-endpoint experiments
performed at baseline, as well as the creation of a survival curve may reveal an impaired
long-term viability in endothelial BRCA2-deficient mice.
Given the single knockout mouse’s baseline phenotype has already established the model
as embryonically viable and without aberration, these mice may be used for further
studies to assess the effect of endothelial cell specific BRCA2 loss under a variety of stress
conditions.
In light of the results of this study, we are obliged to expand the use of this mouse model
to other diseases of the endothelium and DNA damage. These include studies on
doxorubicin-induced cardio- and neurotoxicity, radiation-induced cardiotoxicity, sepsis,
STZ-induced diabetes, and Angiotensin II-induced hypertension.
Such future studies may similarly reveal an indispensable role played by endothelial
BRCA2, thus providing the scaffolding and justification for further investigation into
BRCA2 as a performer in other tissue types and pathologies; potentially influencing the
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direction of screening and treatment of BRCA2 mutation and other DNA damage and
repair molecules.
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